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INTRODUCTION 
Pregnancy is the most important period in women’s life, but it can 
be dangerous also. Pregnancy is a physiological state with increased 
alteration in biochemical and mechanical processes if there are  no 
pregnancy complications during pregnancy ,  the biochemical changes are 
reversible soon after delivery1. Hypertension and proteinuria are the 
important complications of pregnancy and are associated with high 
maternal and perinatal mortality and morbidity2. 
Gestational hypertension  is defined as the presence of systolic 
blood pressure more than 140mm Hg and diastolic blood pressure more 
than 90mm Hg after 20 wks of gestation without proteinuria 
Preeclampsia is defined as presence of systolic blood pressure 
above 140mmofhg and diastolic blood pressure above 90mmofhg, 
associated with proteinuria, edema ( or) both. 
If GHT mother develops generalised tonic clonic type of seizure is 
termed as eclampsia. It may occur before, during, (or) after delivery. 
Sometimes these changes occur earlier when there is multi fetal 
pregnancy ( or) extensive hydatiform changes in chorionic villi3 
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It usually occurs in 5- 10 percentage of pregnancies. It is specific to 
pregnancy and usually associated with high maternal and perinatal 
morbidity and mortality. 
 “BERG and COLLEGUES “ reported that 16% 3201 of maternal 
death in the United States from 1991-1997 were complication of 
pregnancy induced hypertension. During this study black race had 3% 
higher mortality4. Preeclampsia in its severe variety is associated with 
cerebral (or) visual disturbances, oliguria, epigastric pain. 
The elevation of blood pressure is the most important  tool for 
identification of pregnancy induced hypertensive mother. Regular 
monitoring of blood pressure and urine albumin level is essential for 
diagnosing gestational hypertension. 
The visual disturbances (or) oliguria, not a very common 
presentation, but can occur as a result of severe preeclampsia.  
The patho physiological mechanism is characterised by a failure of 
the Trophoblastic invasion of spiral arteries, leading to maladaptation of 
the maternal spiral arterioles, so there is increased vascular resistance of 
the uterine artery and decreased perfusion of the placenta5. 
The spiral arterioles have a significant role in pre eclampsia. The 
structural and physiological changes in the spiral arterioles lead to  the 
development of gestational hypertension.. Development of GHT  is 
usually associated  with change in serum beta HCG and lipid profile.              
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The peripheral edema in the GHT is due to the altered albumin level and 
decrease oncotic pressure leading to capillary leak throughout the body. 
Vascular endothelial dysfunction also plays an important role in 
development of pregnancy induced hypertension, but pathophysiology 
remains unknown6. 
The results from many studies show the relationship between the 
aggravation of hypertensive complication and change in concentration of 
various chemical markers in mother’s serum 7,8. Interestingly change in 
serum beta HCG and lipid profile play an important role for early 
detection of GHT in early second trimester. 
Most important features in GHT are supposed to be due to 
vasospastic phenomenon in kidney, uterus, placenta and brain. Altered 
lipid synthesis leading to decrease in PGI2 : TXA2 ratio is also supposed 
to be an important way of pathogenesis of GHT. 
 Abnormal lipid metabolism seems important in  the pathogenesis 
of GHT too. Association of serum lipid prolife with GHT is highly 
suggested to reflect some new diagnostic tools. The hormonal imbalance 
is a prime factor for the etiopathogenesis of GHT and this endocrinal 
imbalance is well. 
Measurement of serum lipid parameters may be of good predictive 
value in GHT avoiding the costly endocrinal investigations. 
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Maternal complications include: 
1. Abruption placenta 
2. Acute renal failure 
3. HELLP syndrome 
4. Eclampsia 
5. Occipital lobe blindness 
6. Pulmonary edema 
7. Possible complication of caesarean section 
 
Fetal complications include: 
1. Prematurity 
2. Intrauterine growth retardation 
3. Intrauterine death 
4. Fetal distress 
 
These complications of gestational hypertension, could be 
prevented by prompt diagnosis , proper antenatal care and with timely 
intervention. When the GHT sets in very early trimester , close 
monitoring of the patient is necessary. If GHT women are on regular 
follow up and prompt medications, the risks are greatly reduced. Utero 
placental insufficiency is  also reduced by controlling the blood pressure. 
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Decrease in platelet count may be associated with GHT which  
leads to severe bleeding tendencies. It may be  the result of alteration in 
coagulation factors and fibrinogen. Regular monitoring of platelets and 
hepatic enzyme explains the needs for avoiding complication. 
Termination of pregnancy is the treatment for severe preeclampsia/ 
eclampsia. The risk for both mother and fetus is more with continuation 
of pregnancy.  
GHT may progress to severe preeclampsia/ eclampsia with 
uncontrolled hypertension. This is usually preventable by early detection 
of GHT using change in biochemical markers in maternal serum and 
prompt management of hypertension. Known GHT cases should be kept 
under regular follow up. They are advised to check blood pressure 
regularly, routine blood analysis and urine albumin monitoring. There  
are several methods to identify GHT which include isometric hand grip 
test, roll over test, angiotension II pressor response, mean arterial 
response test.  
However these tests have some limitation for screening in view of 
false positive results and subjective nature of interpretation. 
GHT complicates 5-10% of all pregnancies9. In the developed 
countries 16% maternal mortality is due to hypertensive disorders. Early 
detection of GHT and appropriate management is mandatory to decrease 
both maternal and perinatal morbidity and mortality. 
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REVIEW OF LITERATURE 
 1. Clausen et al25 (1980) observed that women with triglycerides 
above 2.4mmol/l had increased risk (OR 5.1; 95% CI 1.1-23.1) of early 
onset  pre eclampsia compared with those with triglycerides levels <1.5 
mmol/l. He concluded that dyslipidemia before 20 weeks of gestation is 
associated with the risk of developing early but not late onset pre 
eclampsia.  
     2. Yamaguchi K et al37 (1998) observed that women with 
triglycerides above 1.7mmol/l had increased risk (0R 6.0 96% RR) of 
development of pregnancy induced hypertension. He also concluded that 
women with elevated triglycerides (sensitivity 89% & positive predictive 
value 88%) are more prone to develop early onset pre eclampsia than the 
control population. 
       3. Vidayabati RK et al24 & hijam et al34 ( 2007) made a study and 
found that  elevated beta HCG and lipid profile in early trimester are 
associated with development of GHT. They examined 164 pregnant 
women between 14-20 weeks of gestation. They found that there was a 
significant association with development of GHT with p <0.0001 valve.  
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           In pregnant women with increased serum beta HCG has   
10.7% increased chances of developing GHT. For one unit increase in 
total cholesterol there was 12.6% increased chance of developing GHT. 
                For every one unit increase in TG, VLDL, LDL there are 
0.3% , 12.4% ,7.1% respectively increased chances of developing GHT. 
One  unit increase in HDL  has 11.4% less chance of developing GHT. 
4. Evruke et al41 (2004) observed that in gestational hypertensive 
patients only total lipid was different than the control group. (p=0.0003). 
In the chronic hypertension group , LDL, and total lipid levels were 
significantly different than the normotensive group. In the pre eclampsia 
group, total cholesterol (>2.5 MoM) , LDL cholesterol, total lipid and 
triglycerides were significantly different from the control group. He also 
concluded that there was no statistically significant change between 
trimesters for high density lipoprotein cholesterol. 
 5. Turpin et al42 in the year 2003 made a study with lipid changes 
in pregnant women associated with the development of gestational 
hypertension. They concluded that women with elevated triglycerides 
level ( > 3.0 MoM) had increased chances (17% ) of developing GHT and 
early onset severe pre eclampsia. They also concluded there was a 
significant association between the elevated VLDL and development of 
GHT, with statistical significance (p <0.001). 
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 6. Daniel A enqrobabrie, William et al43, in the year 2003, 
investigated the relationship between the early pregnancy plasma lipid 
concentration and the risk of gestational hypertension. They identified 
that women who subsequently developed pre eclampsia had 10.4%, 
13.6%, and 15.5% higher concentrations of LDL cholesterol, triglycerides 
and LDL/HDL ratios respectively with P value of < 0.05.The HDL 
cholesterol concentration were 7.0% lower in women with gestational 
hypertension than in the control groups with significant p value of < 0.05. 
7. Gratacos et al44 in the year 2001 made a prospective study and 
found that women with pre eclampsia had high levels of triglycerides ( 
47% versus 13% in control subjects, p <0.001). They also concluded that 
women with elevated LDL level (56% ) are more prone to have early 
onset pre eclampsia than the control group. 
8. In 1995 Kaaja R, Trikkanen M.J, Ylikorkola O et al42 explained 
that women with pre eclampsia shows,elevated level of lipoproteins in 
serum. For one unit increase in TG, VLDL, LDL there are 0.3%, 12.4%, 
7.1% respectively increased chance of developing GHT. One unit 
increase in HDL women has 11.4% less chance of developing GHT. 
9. Clause T, (1998) & Djurovic et al25 (2001) found that 
dyslipidemia seems to be more efficient marker in predicting GHT at 
early second trimester with statistical significant (p <0.05). 
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 Clause T did a study in 1998 in100 pregnant women; in that 54 % 
had elevated triglycerides & among them 48% developed GHT with 
statistical significant value. 
        10. Cekman et al34 (2001) showed that plasma triglycerides and LDL 
levels were significantly higher in GHT subjects than controls. They did a 
study in 126 pregnant women, among which 78% had elevated 
triglycerides, out of which 56 people developed GHT with significant 
association (P <0.05). In that study they identified the strength of 
association between LDL and GHT with an odds ratio 1 and relative risk 
of 3.2%.  
11. Wakatsuki et al36 (2000) & Williams et al43 (2001) investigated 
the relationship between early pregnancy plasma lipid concentration and 
risk of GHT. They identified that women who subsequently developed 
GHT had 12.4% , 15.6% and 12.5% higher concentrations of LDL 
cholesterol, triglycerides and VLDL respectively with p value of  <0.05. 
The HDL cholesterol concentration was 5.0% lower in women with GHT 
than in control groups with P value of < 0.05. They focused   mainly on 
serum levels of LDL. They identified that there were significant 
relationship between elevated LDL & GHT. With this analysis they found 
that the sensitivity & positive predictive value of LDL against GHT was 
86% & 92% respectively. 
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12. In the year 2003 Istam et al36 identified that women with 
reduced level of HDL ( less than 65 mg/dl) are  more prone to develop 
GHT & early onset severe pre eclampsia. They did a study in 100 
pregnant women. Women with reduced HDL level (42) are categorised as 
study group. They compared the HDL level in both the population & 
found that there was a significant correlation between GHT and reduced 
HDL level (p<0.01). 
13.  In the year 1996,  Ray JG , Vermeulen MJ, Schull MJ et al30 
found that elevated levels of TG (>200 mg/dl) was  associated with 4 
times increased risk of development of GHT than normal. They found 
that strength of association was (RR) 4%. There is a significant 
correlation between TG & GHT with significant association.    
14. In the year 1998 Lima VJ, Andrade CR, Ruschi et al31 also 
found  that TG  contributes to the development of pre eclampsia, which is 
characterised by proteinuria and high blood pressure. 
They analysed a total of 150 pregnant women, of which75 were 
GHT mothers &75 of them were normotensive. They did a  TG analysis 
in both the groups. In GHT group 62 of them had elevated TG. In 
normotensive only 20 of them had elevated TG level. There was a high 
sensitivity and specificity between TG & GHT, 83.8% & 92% 
respectively. 
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15.  In the year 1999 Yaron et al21 found that elevated beta HCG 
was significantly associated with GHT. They did a study in 250 pregnant 
women with elevated beta HCG & found that  beta HCG > 2.5 MoM was 
significantly associated with GHT.   
16. In the year 1992 Aquilina & Ellis p et23 al found a significant 
association between the beta HCG and elevated inhibin A associated with 
development of GHT and pre eclampsia. They did cross sectional study in 
200 populations; in that women with elevated beta HCG more than 2.5 
MoM in early second trimester were followed up till their delivery. 95 of 
them had elevated beta HCG value, of which 68 developed GHT. They 
found a correlation between beta HCG & GHT. They found that there 
was a statistical significance between beta HCG & GHT. They found that 
the sensitivity of beta HCG was 83% & specificity was 88%. Positive 
predictive value was 92%. With these findings they concluded that beta 
HCG can be used as a good predictor for GHT  in early second trimester.   
17 .In the year 2003 Vidyabati RK25 , hijam danina et al34 done a 
study with beta HCG and lipid profile in early second trimester. They 
examined 164 pregnant women between 14 -20 wks of gestation, in 
which twenty nine cases developed GHT, while 135 cases remained 
normotensive. The serum beta HCG increased very significantly 
(p<0.001) in those women who developed GHT.  They proved that, for 
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one unit increase in the beta HCG, pregnant women had 3.7% increasing 
chance of GHT. 
18.  Wenstorm et al 45(2000) found that for every one unit increase 
in serum beta HCG, pregnant women had  10.7% increasing chances 
of developing GHT. For one unit increase in total cholesterol associated 
with 12.6% increased chance of developing GHT. 
19. Pouta et al41 found that increased level of serum beta HCG 
more than 25000 mIU /l is associated with the development of early onset 
severe pre eclampsia before 28 weeks of gestation & eclampsia. They did 
a study in 45 GHT women with elevated beta HCG value, in which 28 
women developed severe pre eclampsia before 28 weeks of gestation. 
There was a statistical significant (p 0.01%) between elevated beta HCG 
& development of early onset severe pre eclampsia.  
20. Morssink et al43 found that cases with elevated beta HCG had 
increased incidence of GHT & early onset severe pre eclampsia. They 
found that one fold increase in beta HCG , had 12.4% increased chance of 
developing GHT. They concluded that, beta HCG has 92% sensitivity 
against GHT.  
21. In 1999 taital stojikovic mikic research fellow found that 
elevated serum beta HCG in early second trimester is a useful predictor 
for early diagnosis of GHT. They published an American journal in the 
year 2000. A case control study was done in 250 women. Of them 125 
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were found to be normotensive & 125 were found to have GHT. Among 
the GHT population, 92 had elevated beta HCG. They did a statistical 
correlation between elevated beta HCG & GHT. With these results they 
concluded that women with elevated beta HCG had 7.2% increased 
chance of developing GHT. 
22. In the year 2003 , Durick K, S krabin S, lesin jet et28 al found 
that  second trimester elevation of serum beta HCG is associated with 
development of GHT & low birth weight & IUGR babies. In the study 
they had 45 GHT women, of which 12 of them had low birth weight 
babies & 17 of them had IUGR babies & perinatal mortality was 14%. 
23.Wenstrom KD quen J et al45 (2000) found that there was an 
elevated second trimester serum beta HCG in singleton pregnancies and 
an adverse pregnancy outcome including development of GHT, IUGR, 
low birth weight babies and early onset severe pre eclampsia. In that 
study they had proven that most of the low birth weight babies were due 
to iatrogenic prematurity for severe pre eclampsia. 
24. Gomen R, Perez R, David M et al (2003) identified that women 
with elevated serum beta HCG were associated with increased risk of 
development of GHT & IUGR. Women with elevated beta HCG more 
than 3.5 MoM  were more prone to have IUGR babies than others. In this 
study they had high NICU admission (28%) in GHT population & most 
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of them got admitted for low birth weight.  But there was no significant 
neonatal mortality. 
25. In the year 2003Vallient et al26 demonstrated that free beta 
HCG was a marker of high risk for GHT & associated with small for 
gestational age .They did a study in 192 pregnant women. Women with 
beta HCG > 3.5 MOM is taken as study group. In which 87 of them had 
elevated beta HCG. In the study group 24 of them developed GHT in 
third trimester. In which 12 of them had IUGR baby .They also found that 
women with elevated serum beta HCG were associated with increased 
risk of IUGR baby with statistical significance value (p <0.01). 
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HYPERTENSIVE DISORDERS IN PREGNANCY 
 
 Hypertensive disorder complicating pregnancy is common and 
form one of the deadly triad that contributes for increased maternal 
mortality and morbidity 
Identification of GHT in women should be done as early as 
possible. Treating GHT at the initial stage is easier when compared with 
treating patient with complications..Enhanced surveillance will be help 
in identifying high risk pregnant women .. Early detection and proper 
management helps to prevent progression of disease. Proper treatment at 
the initial stage of the disease is necessary for good pregnancy outcome 
for both mother and fetuS. However why pregnancy induces these 
vascular changes remains an unsolved problem in obstetrics. 
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CLASSIFICATION 
According to National high blood pressure education 
program (2000) 
Hypertensive disorder classified into 5 stages9 
1. Gestational hypertension 
2. Preeclampsia 
3. Eclampsia 
4. Preeclampsia super imposed on chronic hypertension 
5. Chronic hypertension 
 
GESTATIONAL HYPERTENSION 
Defined as 
 1. Measurement of systolic blood pressure more than 140mmhg 
(or) diastolic blood pressure more than 90 mmofHg for the first time in 
pregnancy after 20weeks of gestation 
                      2. Not associated with proteinuria 
                      3. Blood pressure returns to normal within 12weeks of 
postpartum period. 
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PREECLAMPSIA 
Defined as  
1.  Elevated blood pressure with proteinuria, edema may be present. 
     2. Proteinuria more than 300 mg in 24 hrs urine (or) 30 mg/dl. This is 
equal to 1(+) dipstick test in random urine sample. 
Classified into two types: 
1. Mild preeclampsia 
2. Severe preeclampsia 
Severe preeclampsia is considered if any of the following is present 
• Systolic blood pressure more than 160 mmhg ( or) 
diastolic blood pressure more than 110mmhg. 
• Proteinuria 5gm per 24 hrs urine sample 
• 2 (+) in dip stick random urine test 
• Thrombocytopenia ( platelets < 1laks/cumm) 
• Symptoms like persistent headache, visual 
disturbance, epigastric pain 
• Microangiopathic hemolysis 
• Elevated serum creatinine 
• Pulmonary oedema 
• IUGR/ oligohydramnios 
• Oliguria 
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ECLAMPSIA 
If GHT mother develops generalised tonic clonic type of seizure is 
termed as eclampsia. It may occur before, during, (or) after delivery. 
PREECLAMPSIA SUPERIMPOSED ON CHRONIC 
HYPERTENSION. 
 Defined as known hypertensive patient developing proteinuria 
after 20 wks of gestation. 
                                  CHRONIC HYPERTENSION 
Blood pressure more than 140/ 90 mmofHg before pregnancy (or) 
before 20 wks gestation (or) hypertension diagnosed after 20 wks of 
gestation and persistent after 12 wks of postpartum. 
INCIDENCE & RISK FACTORS 
GHT  usually affects young and nulliparous women Incidence.(5-10%) 
RISK FACTORS: 
• Age ( young & elderly primi) 
• Interval from last pregnancy > 10 yrs 
• Obesity BMI > 35kg/ m2 
• Multifetal gestation 
• Genetic predisposition 
• Hydramnios 
• Vesicular mole 
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• Hydrops fetalis 
• Chronic hypertension 
• Maternal diabetics 
• Renal disease 
• Anti phospholipids antibody syndrome 
• Systemic lupus erythematosus 
• H/O smoking 
• Abnormal uterine artery Doppler at 18 -24 wks 
 
AGE: 
        GHT is more common in young women. Incidence of preeclampsia 
& eclampsia is more in elderly women more than 35 yrs. 
GENETIC FACTORS: 
       In 1873 Elliot described familial nature of the disease. This theory 
was reviewed by chesley (1968). He identified both parents  contribute to 
genetic risk. There is presence of increased susceptibility of inherited 
genes from GHT mother to the fetus, the gene is capable of triggering 
GHT.  
                   It is a “MULTI FACTORIAL POLYGENIC SYNDROME”15 
Responsible genes: 
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1. MTHFR gene affecting methylene tetra hydrofolate 
reductase 
2. Factor V ( leiden) gene 
3. Angiotensinogen gene (AGT) 
4. HLA genes causing immunological tolerance 
5. NOS3 gene affecting endothelial nitric oxide production 
6. Prothrombin factor II gene 
7. ACE gene 
ETIOLOGY: 
• Despite of lot of researches exact cause of GHT remains 
unknown 
• More common in women who are 
1. Exposed to chorionic villi for the first time 
2. Exposed to superabundance of chronic villi ( as with 
hydatiform mole/ twins) 
3. Women with pre-existing vascular disease 
4. Genetically predisposed 
According to sibai (2003) the probable cause include 
a. Abnormal Trophoblastic invasion of uterine vessels 
b. Immunological intolerance between maternal & feto 
placental tissues 
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c. Maternal maladaptation to inflammatory /cardiovascular 
changes 
d. Dietary deficiencies 
e. Genetic influences 
 
IMMUNOLOGICAL  THEORY: 
 Immunological as well as genetic and endocrine mechanisms are 
involved in pathogenesis of GHT 
 The risk of GHT is increased with deficient blocking antibodies 
against the antigenic sites on the placenta (or) with increase no of 
antigenic sites on the placenta (Eg : multiple fetus). Some studies 
identified that there is no association between GHT & complement factor 
C3, C3F. 
GENETIC THEORY: 
In 1970 Cooper and Liston identified GHT is dependent upon 
single recessive gene but multi factorial inheritance cannot be excluded. 
DIETARY DEFICIENCIES: 
Calcium deficiency may be associated with GHT . Some studies 
revealed daily supplement of calcium 2g/day in mid trimester reduce the 
incidence of GHT 
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PATHOGENESIS 
GHT women show changes in vasomotor activity, coagulation 
system, plasma volume , these disturbances may be due to endothelial 
cell dysfunction ( or) activation 
VASOSPASM :  
                     Basic pathophysiology of  GHT is “ VASOSPASM” 
                                    Vasoconstriction 
                                                
                             Resistance to blood flow 
 
                        Development of arterial hypertension 
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ABSENCE OF SPIRAL ARTERIOLES REMODELLING: 
Pathogenesis of GHT starts with placenta.  
 
DEVELOPMENT OF UTEROPLACENTAL VESSELS: 
Occurs in two stages: 
First stage of invasion: 
             This stage occurs upto 12 weeks. The cytotrophoblasts of the 
placenta invade the spiral arterioles upto the decidual-myometerial 
interface. 
Second stage: ( between  12-16 wks) 
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This stage involves invasion of intra myometrial segments of spiral 
arteries usually the cytotrophoblasts of the developing placenta migrates 
through the decidua and myometrium and invade the tunica media of the 
spiral arteries which supply blood to the fetus.  These changes lead  to 
transformation of small muscular arterioles to large low resistance 
vessels. These changes occur at end of the first trimester and completed 
by 18-20 wks.. 
In GHT spiral arteries fail to penetrate the myometrial segment. So 
spiral arteries remains narrow.. There is  hypoperfusion of placenta 
leading on to placental ischemia.. Because of this there is a maternal 
endothelial dysfunction. 
In 1980, Dewolf et al examined the arterioles from the placental 
implantation site using electron microscopy. They found that in early 
state there is damage of endothelial cells, accumulation of lipids in the 
myointimal cells resulting in narrowed lumen. 
 
IMMUNOLOGICAL TOLERANCE: 
 Immunologists studied that, abnormal immune protective  
mechanism, which is present in  the mother against the fetus 
results in the development of GHT. 
 To support this theory incidence of GHT is reduced in 
immunosuppressive patient. 
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 When compared with normotensive patient , GHT patient have 
reduced no of helper T cells in early second trimester. 
 TH1/ TH2 imbalance was mediated by adenosine, which is 
found to be higher in GHT. 
 
Placental changes in the GHT were similar with rejected kidney 
after transplantation. With this evidence, to support this theory, there is 
loss of maternal tolerance to the paternally derived placenta and fetal 
antigen. Women with GHT having reduced amount of messenger RNA 
for HLA –G. Cytokines mainly TNF alpha, IL 2 , IL 6 are the mediators 
of immune maladaptation in GHT patients. 
. 
ENDOTHELIAL CELL ACTIVATION: 
Intact endothelium has anti coagulant property. It releases the nitric 
oxide, so it reduces the vascular smooth muscle response to agonist. 
Damaged endothelium  secretes pro coagulant, reduced nitric oxide 
production, so there is increased sensitivity to pressor agents. 
PROSTAGLANDINS: 
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Prostacyclin : thromboxane ratio is decreased . Because of this decreased 
ratio, endothelial cells are more sensitive to vasopressor angiotensin II , 
which  finally leads to vasoconstriction. 
 
NITRIC OXIDE: 
 L- Arginine produces nitric oxide in endothelial cells. Nitric oxide 
is a potent vasodilator. In GHT patient NO production is reduced. 
Because of this there is increased sensitivity to vasopressor agents , 
ultimately there is increased mean arterial pressure. 
 
OXIDATIVE STRESS: 
This hypothesis explained that activated leukocytes are  
responsible for development of GHT . The decidua contains a large group 
PGI2 & Prostacyclin
Thromboxane 
A2
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of cells, which on activation releases noxious agent like TNF alpha, 
leukotrienes. They are responsible for oxidative stress in the body. 
 
ENDOTHELIN:  
It is produced by human endometrium , it is a potent vaso 
constrictor. Endothelin levels are  increased in GHT women. Some 
evidence suggests that magnesium sulphate decreases the endothelin 1 
concentration. 
 
ANGIOGENIC & ANTI ANGIOGENIC PROTEIN: 
The balance between these proteins is responsible for normal 
development of placenta. In GHT there is increased production of anti 
angiogenic proteins, resulting in endothelial dysfunction. Use of anti 
angiogenic proteins in the prediction & diagnosis of GHT is a new 
research  going on now. 
2 Main anti angiogenic proteins used in research: 
1. Soluble endoglin 
2. Soluble FMS like tyrosine kinase 1 
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SOLUBLE ENDOGLIN:  
              It is a 65 kdalton , derived from placenta. It inhibits binding  of 
TGF β binding with endothelial receptors which indirectly reduces nitric 
oxide release from the endothelium. 
 
SOLUBLE FMS LIKE TYROSINE KINASE 1: 
It reduces the vascular endothelial growth factor & placental 
endothelial growth factor and thus leads to endothelial dysfunction. 
Both these anti angiogenic proteins are elevated in maternal serum 
before the development of GHT. So it can be used as an early marker for 
prediction of GHT. 
RETENTION OF SODIUM: 
In normal pregnancy plasma volume, glomerular filtration and 
renal flow increases, but in GHT all these parameters are reduced. This 
leads to retention of sodium which increases the vasopressor sensitivity. 
All the signs & symptom of GHT & its complication can be 
explained by the  response to generalised endothelial dysfunction. 
1. Increased vascular permeability leads to proteinuria and edema 
2. Changes in vascular tone of endothelial cells will cause 
hypertension 
3. Procoagulants  expression leads to coagulopathy 
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Endothelial dysfunction in the vasculature of brain, liver, kidney & 
placenta  causes headache, seizure, epigastric pain, visual disturbances 
and intrauterine fetal growth restriction. 
 
PATHOLOGICAL CHANGES: 
                            GHT is a two stage disease 
1. ASYMPTOMATIC STAGE: 
Abnormal placental development during first trimester leads to 
placental insufficiency and release of placental materials in maternal 
circulation. 
 
2. SYMPTOMATIC & PROGRESSION DISEASE: 
Because of these substance, there was a development of  hypertension, 
proteinuria, & organ involvement. 
CARDIOVASCULAR SYSTEM: 
Blood pressure = cardiac output X total peripheral resistance. 
  Normally total peripheral resistance decreases but in GHT it 
increases. This is the main reason for elevated blood pressure in GHT 
women. GHT women  are more prone for pulmonary edema despite the 
normal ventricular function. This is due to endothelial – epithelial leak,  
compounded by decreased oncotic pressure from low albumin 
concentration. 
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HAEMATOLOGICAL SYSTEM: 
Normally there is a disproportionate increase between plasma 
volume and RBC volume leading to physiological anemia of pregnancy. 
Plasma volume expansion is reduced in GHT .  Intra vascular space is  
also contracted. 
Because of this hemoconcentration hematocrit increases. Any 
attempt to expand the intra vascular space leads to increase in the 
pulmonary capillary wedge pressure which  ends in pulmonary edema 
because of capillary leak. 
Vasospasm is a main pathophysiology in GHT which leads to 
endothelial injury. Endothelial injury end up in micro angiopathic 
hemolysis, which results in anemia , fragmentation of RBC, 
thrombocytopenia. 
BLOOD & COAGULATION: 
 The most common haematological abnormality is 
thrombocytopenia. It is more common in pre eclamptic  patient which 
may be life threatening. Endothelial dysfunction causes release of tissue 
factor which act on coagulation system, resulting in disseminated 
intravascular coagulation. 
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THROMBOCYTOPENIA: 
Described by stancke in 1922 in patients with severe GHT. All 
patients with GHT  should be routinely examined for platelets. Intensity 
of thrombocytopenia depends on duration & severity of GHT. Less than 1 
laks/cumm of platelet indicates severe disease. Thrombocytopenia is 
associated with higher maternal and fetal morbidity & mortality. 
 
HELLP SYNDROME: 
            It is an acronym indicating 
Hemolysis, Elevated Liver Enzyme, Low Platelets. It is common in 
severe preeclampsia which indicates hepatocellular necrosis. 
COAGULATION: 
1. Decreased anti thrombin III 
2. Decreased protein C & S 
3. Decreased plasma fibrinogen 
4. Increased FDP 
5. Increased fibrinopeptides A& B 
ENDOCRINE SYSTEM: 
Angiotensin II, catecholamine & vasopressin play an important 
role in elevation of blood pressure & increase the vascular resistance. 
Sensitivity of vascular endothelium to angiotensin II occurs 8-12 wks 
prior to the onset of clinical symptom. 
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Indomethacin & aspirin  are prostaglandin inhibitors which  
decreases the angiotensin II sensitivity on the vascular endothelium. 
 
RENAL SYSTEM: 
In GHT there is  increased resistance of renal afferent arterioles 
which leads to reduced renal perfusion. It also reduces the glomerular 
filtration rate. Glomerular endotheliosis also occurs in GHT which block 
the filtration barrier. Sodium concentration in urine is elevated. 
 
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM: 
It is very important for maintainence of blood pressure & blood 
sodium level. In normal pregnancy plasma renin concentration& its 
activity, angiotensin II & aldosterone levels are elevated. Normal 
pregnant women have reduced refractoriness to angiotensin II. 
But GHT patient lost their refractoriness to angiotension II. It is 
usually demonstrated by pressor response test at 18-22 wks of gestation. 
LIVER : 
Periportal haemorrhagic necrosis is the commonest pathological 
lesion in GHT. It usually manifest as upper epigastric pain & tenderness. 
It is associated with alanine transterase & aspartate transferase. It usually 
indicates severe form of disease. Area of infarct may be seen in liver 
which is usually diagnosed by CT/ MRI. 
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BRAIN:   
Brain involvement in GHT was first diagnosed at autopsy 
specimen with severe disease.  But now imaging studies give us very 
important information of GHT changes in the brain. 
Common anatomical lesion: 
1. Intracerebral haemorrhage 
2. Cortical & sub cortical petechial haemorrhage 
3. Haemorrhage in pons/ basal ganglia 
4. Subcortical edema 
 
Proposed theories behind the cerebral pathology  
  Theory  : I 
Due to vasospasm of cerebral vessels, there is diminished blood 
flow,to the brain  resulting  in ischemia, infaction, edema. 
 Theory: II 
Sudden elevation of blood pressure may exceed the normal auto 
regulatory capacity of the cerebral vessels. 
 
UTEROPLACENTAL PERFUSION: 
Compromise in utero placental perfusion is common in GHT which 
is mainly due to vasospasm.. 
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LIPID METABOLISM: 
The hypothesized mechanisms for dyslipidemia and GHT association are 
as follows 
1. Elevated plasma lipid and lipoprotein may induce endothelial 
dysfunction secondary to oxidative stress. They also noted 
that dyslipidemia may impair trophoblastic invasion thus 
contributing to a cascade of pathophysiological events that 
leads to development of GHT. 
2. Pathological process of pre eclampsia via dysregulation of 
lipoprotein lipase resulting in a dyslipidemic lipid profile. 
Sera from pre eclamptic women had  higher ratio of  both 
FFA to albumin and increased uptake of FFA, which are 
further esterified to triglycerides. 
3. Possible mechanism may be via metabolic syndrome. 
Metabolic characteristics of “ insulin resistance syndrome” 
namely hyperinsulinemia and hyperuricaemia are also present 
in GHT. Women with history of pre eclampsia as compared 
with BMI matched counterparts without such a history, have 
higher circulating concentrations of fasting insulin, lipid and 
imflammatory coagulation factors years after delivery. 
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These genetic and environmental factors that contribute to the 
pathogenesis of metabolic syndrome and related vascular disorders may 
also be important in determining the occurrence of GHT 
 At present these hypothesis are the subjects of extensive 
investigations, for development of GHT 
1. Placental ischemia 
2. Altered endothelial cell function, possibly secondary to 
altered lipid metabolism 
3. Immune maladaptation. 
 
Serum triglyceride & total cholesterol were found to be high & 
HDL was significantly low in GHT patient. 
Work in the field of cardiovascular research has shown that serum 
lipids have a direct  effect on endothelial function and that abnormal 
serum lipid profiles  are associated with endothelial dysfunction. As such 
the potential role of abnormal lipid metabolism in the genesis (or) 
expression of GHT is a subject of increasing interest. Lipids & 
lipoprotein levels undergo dramatic changes in pregnancy presumably to 
supply nutrients to the growing fetus. Plasma concentration of 
triglyceride & cholesterol increase approximately 30% and 50%  
respectively 
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•       Although the presence of hyperlipidemia has been documented 
in a normal pregnancies the magnitude & significance of the lipid 
changes in pregnancies complicated by GHT has not been well 
defined. Increases in plasma cholesterol , triglycerides & VDRL 
has been noted 
           Histopathological finding noted in the uterine spiral arteries in 
patient with GHT may theoretically be associated with changes in serum 
lipid levels. In women with pre eclampsia , triglyceride concentrations 
climb substantially above these observed in normal pregnancy. It occur 
earlier before the appearance of clinical manifestations of the disorder. 
 
•  This study was undertaken in order to evaluate the lipid changes  
in pregnancies developing hypertensive disorders. 
 
Total Plasma Lipid : 400 – 600 mg/ dl 
                   Total cholesterol   : 140 – 200 mg/ dl 
                    HDL level                : 35-75 mg/dl 
                    LDL level                 : 80 – 130 mg/ dl 
                   Triglycerides level   : 40-150 mg/dl 
                   FFA  levels                : 10- 20 mg/dl 
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 One third of plasma lipids are cholesterol, one third is triglycerides 
& one third is phospholipid. Lipids are insoluble in water, they need the 
help of carriers in plasma . So they are  complexed with proteins to form 
lipoproteins. The protein part of the lipoprotein is called apolipoprotein. 
 
CLASSIFICATION OF LIPOPROTEINS: 
  There are five major classes of lipoproteins based on their 
separation by electrophoresis are 
 
1. CHYLOMICRONS: 
 They are synthesised in the intestine & transport  exogenous 
triacylglycerol  to various tissue. They consist of 90%  quantity of 
lipid & 10%  concentration of proteins. The chylomicrons are the 
least in density & longest in size. 
2. VLDL:  
 They are produced in liver and intestine and are responsible 
for the transport of endogenously synthesised triacylglycerols 
3. LDL:    
Formed from VLDL, in the blood circulation. They transport 
cholesterol from liver to other tissues. 
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4. HDL:  
 Mostly synthesised in liver. They contain highest protein 
concentration. 3 different fractions of HDL (1, 2, 3 ). Identified by 
ultracentrifugation.It helps in transport of cholesterol from 
peripheral tissues to liver. 
5. FFA :  
        Usually it is  bound to albumin. Each molecule of albumin 
carry 20-30 molecules of free fatty acids. This lipoprotein cannot 
be separated by electrophoresis. 
 
APOPROTEINS: 
 The protein part of lipoprotein is called apolipoproteins (or) 
apoprotein. All apoproteins are mainly systhesised in liver but small 
quantities are produced from almost all organs. Intestinal cells produce 
small quantities of apo- A. Apart from solubilising the lipid part, the 
protein components have specific functions. They are important in 
1. Maintaining the structural integrity of the lipoprotein 
2. Regulating certain enzymes which act on lipoproteins 
3. Receptor recognition 
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 METABOLISM OF LIPOPROTEINS: 
 Lipoprotein metabolism can be thought of as two cycles, one 
exogenous & one endogenous, both centered on the liver. These cycles 
are interconnected. 
ENZYMES INVOLVED IN LIPID TRANSPORT: 
1. Lecithin choseterol acyl transferase 
2. Lipoprotein lipase 
3. Hepatic lipase 
4. Mobilizing lipase 
 
DIAGNOSTIC IMPORTANCE OF LIPOPROTEINS: 
 The blood levels of certain lipoproteins have diagnostic 
importance. The ratio of HDL cholesterol to that in the LDL can be used 
to evaluate susceptibility to the development of heart disease. For healty 
person LDL/HDL ratio is 3: 5. Raised plasma LDL- Cholesterol 
concentration is associated with an increased risk of ischemic heart 
disease. Raised plasma concentration of HDL cholesterol is associatd 
with decreased risk of ischemic heart disease and seems to have 
protective effect. 
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Increased LDL and decreased HDL associated with increased risk 
of GHT. The exact nature of the protective effect of HDL is not known. 
DISORDERS OF LIPOPROTEIN METABOLISM: 
1. Hyperlipoproteinemia 
2. Hypolipoproteinemia 
HYPERLIPOPROTENEMIA: 
                                  Primary: familial hypercholesterolemia 
                                  Secondary :  
1. Renal disease 
2. Nephritic disease 
3. Cirrhosis of liver 
4. Hypothyroidism 
5. Diabetes mellitus 
6. Alcohol abuse 
7. Women taking estrogen containing oral 
contraceptive. 
(these disease are included in exclusion criteria) 
HYPOPROTEINEMIA: 
                Primary:  Abetalipoproteinemia 
                                 Tangier’s  disease 
                Secondary: severe malabsorption 
                                     Chronic liver disease 
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BETA HCG: 
It is a glycoprotein with the highest carbohydrate content of any 
hormone in the human body. Like all glycoproteins , it consists of two 
subunits: α ( 92 amino acids) and β (145 amino acids), of which the α sub 
unit is structurally and immunologically similar in HCG ,LH,FSH and 
TSH. 
Human chorionic gonadotropin is synthesised by the 
syncytiotrophoblast cells of the placenta even before implantation and 
can be detected in the peripheral blood by radioimmunoassay soon after 
implantation and well before the missed period. 
The titres are increased in twin pregnancy, hydatidiform mole and 
choriocarcinoma. The titres are also high if the fetus has Down syndrome. 
The titres are low in ectopic pregnancy and threatened abortion.. The 
concentration of HCG is more on the maternal side and placenta than on 
the fetal side..  
Placenta is the known primary trigger of pregnancy induced 
hypertension. Women with GHT usually have primary placentosis/ 
abnormal placentation. Beta HCG is secreted in abundance from placenta. 
Beta HCG in mid trimester is elevated in patients with chromosomally 
normal fetus who later on develop pre eclampsia.  
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There is a general agreement that the placenta remains the main 
source of beta HCG in patients with GHT, but whether the cause of high 
circulating levels of hormone is placenta overproduction is still debated. 
It is may be due to abnormal placental invasion (or) placental immaturity. 
It may also be linked to the trophoblast response to hypoxia with 
the development of a hypersecretory state. A role of placental factors is 
further supported by findings of increased peroxidation and oxidation 
stress in placentas of women with GHT. Oxidative stress secondary to 
reduced placental perfusion leads to endothelial dysfunction linking the 
two stages of the syndrome. 
• Compared with normal pregnancies the placenta of patients with 
unexplained elevated maternal betaHCG levels in the seond 
trimester tend  to be larger and tend to have an increased density of 
betaHCG positive trophoblast along with an increased intensity of 
betaHCG immunostaining within the placental villi 
  
NORMAL HCG LEVEL DURING PRGNANCY: 
Human chorionic gonadotropin can be detected in maternal blood 
and urine 8-10 days after fertilization . The serum level is 100 mIU/ml at 
2 weeks after fertilization, peaks to 100,000 mIU/ml at 10 weeks and 
declines. By 14 weeks , a nadir is reached (20,000- 25,000) and 
maintained for the rest of the pregnancy. 
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Estimation of serum β HCG levels was done by enzyme linked 
immune absorbent assay. The quantitative determination of chorionic 
gonadotropin in serum carried out by microplate immune enzymometric 
assay, with kits obtained from monobind. 
 
HIGH LEVELS OF VALUE: 
Seen in  Multiple pregnancy , gestational Trophoblastic disease, 
Down syndrome, erythoblastosis fetalis. 
 
LOW LEVELS OF VALUE: 
Found in ectopic pregnancy and early pregnancy loss. Both these 
category patients were excluded from the study. 
COMPLICATION: 
MATERNAL: 
CENTRAL NERVOUS SYSTEM: 
• Eclampsia 
• Cerebrovascular accident 
• Retinal detachment 
• Cortical blindness 
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RESPIRATORY SYSTEM: 
• Pulmonary edema 
• Acute respiratory distress syndrome 
RENAL SYSTEM: 
• Renal cortical necrosis 
• Renal tubular necrosis 
• Renal failure 
LIVER : 
• HELLP syndrome 
• Hepatic rupture : most serious complication 
• Fatty liver: very rare disease characterised by 
microvesicular hepatic steatosis 
HAEMATOLOGICAL : 
1. Disseminated intra vascular coagulation  
PLACENTA: 
• Abruption placenta 
FETAL COMPLICATION: 
 “GHT is considered as maternal disease, fetus is incidental 
participant, in fetal point of view it is a fetal disorder, and mother is 
incidental participant”. 
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Normal placental changes which is more extensive in case of    pre 
eclampsia includes 
1. Increased syncytial knots 
2. Increased number of true infarcts 
3. Cytotrophoblast proliferation 
4. Villous necrosis 
5. Maternal decidual arteries fibrinoid degeneration. 
Because of this there is 
1. Increased secretion of chorionic gonodotropin 
2. Increased secretion of steroid hormones 
3. Deterioration of acute transport mechanism of vital 
aminoacids 
All the factors lead to: 1. Fetal hypoxia and IUGR 
2. IUD 
3. Prematurity- mainly iatrogenic 
4. Respiratory distress syndrome 
5. Drug induced side effects in fetus 
 
HELLP SYNDROME: 
HELLP syndrome was first discovered by Weinstein, in the year 
1982. 
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It comprises Hemolysis, Elevated liver enzyme, Low platelet 
count. Incidence is about 0.2- 0.6%. It usually present with nausea, 
vomiting, epigastric pain. 
 
CRITERIA FOR DIAGNOSIS:   
HEMOLYSIS: 
1. Abnormal peripheral smear: burr cells,  schistocytes 
2. Bilirubin: > 1.2 mg/ dl 
3. Lactate dehydrogenase > 600 u/l 
4. Low serum haptaglobulin 
 
ELEVATED LIVER ENZYMES: 
1. SGOT > 70 u/l 
2. LDH > 600 u/l 
 
LOW PLATELETS: platelet count < 1 laks/cumm 
DIFFERENTIAL  DIAGNOSIS: 
 Cholestasis of pregnancy 
 Acute fatty liver of pregnancy 
 Viral hepatitis 
 Haemolytic uremic syndrome 
 Thrombotic thrombocytopenic purpura 
  
 
47 
 
MANAGEMENT: 
 Termination of pregnancy 
 Prophylactic anti- convulsant to be given 
 Platelet count and LDH level return to normal within 
72 hrs after delivery. So it can used as markers for 
follow up. 
 
PREDICTION AND PREVENTION OF GHT: 
Several attempts were done to find out the early markers of 
impaired placenta perfusion, faulty placentation, & endothelial cell 
activation and dysfunction. Till now there is no reliable test to predict pre 
eclampsia. 
 Conde agudeolo and associates , provided the review for the tests 
in the year 2009. 
Tests for vascular resistance: 
1. Isometric handgrip/ cold pressor test 
2. Angiotensin II infusion test 
3. Mid trimester mean arterial pressure 
4. Platelet angiotensin II binding 
5. 24 hours ambulatory blood pressure monitoring 
6. Uterine artery Doppler 
7. Fetal transcranial Doppler velocimetry 
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Tests for placental unit endocrine dysfunction: 
1. Human chorionic gonadotropin 
2. Alpha feto protein 
3. Estriol 
4. Pregnancy associated protein A 
5. Inhibin A 
6. Activin A 
7. Placental protein 13 
8. Corticotrophin releasing hormone 
 
Test for renal dysfunction : 
1. Serum uric acid 
2. Micro albuminuria 
3. Urinary calcium/ kallikrein 
4. Microtransferrinuria 
5. N – acetyl –β- glucosaminidase 
 
Test for endothelial dysfunction: 
                        1. Platelet count  
                       2. Fibronectin 
                       3. Endothelial adhesion molecule 
                      4. Prostaglandins and thromboxane 
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                      5. C- reactive protein and cytokines 
                      6. endoglin 
 
Miscellaneous: 
1. Anti thrombin III 
2. β 2 glycoprotein 
3. Atrial natriuretic peptides 
4. lipid profile 
 
Mean arterial blood pressure: 
MAP = diastolic pressure + 1/3 pulse pressure 
Usually there is a normal fall in blood pressure in mid trimester.  
Those who don’t have normal fall with elevated mean arterial pressure 
more than 90 mm hg in second trimester are at risk of developing pre 
eclampsia. 
 
Roll over test: 
Ask the women to turn from left lateral to supine position. If 
increase in diastolic blood pressure 20 mmof Hg (or) more is considered 
as test positive. 
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Angiotensin sensitivity test: 
In normal patient there is refractoriness to angiotensin between 28 
– 32 wks of gestation, it is usually lost in GHT. This test is based on 
above fact infuse angiotensin < 8 ng/kg/min, if the pressor response  
occurs  with the above dose they are more likely to develop GHT. 
Sensitivity is about 80%  but it is invasive test. 
 
Uterine artery Doppler: 
Non pregnant women: 
Reduced diastolic flow and notching of uterine artery 
Normal pregnancy: 
Because of Trophoblastic invasion, flow increased and notch 
disappears. 
“PERSISTENCE OF DIASTOLIC NOTCH (OR) INCREASED 
RESISTANCE IN THE UTERINE ARTERY AT 20 -22 Wks indicate 
DEFECTIVE TROPHOBLAST INVASION”. 
The latest combination method for prediction of GHT is uterine 
artery Doppler with measurement of PAPPA – A & PLACENTAL 
PROTEIN 13. 
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METHODS OF PREVENTION: 
1. Low Salt Diet: 
Earliest research found that salt restriction will prevent GHT ( 
De Snoo 1937). Knuist & collegues reported in 1998 , salt restriction 
not preventive for GHT. 
 
2. Calcium Supplementation: 
                     Calcium supplementation with 1.5-2g calcium carbonate (or) 
elemental calcium from various preparations has shown to reduce the 
incidence of pre eclampsia almost by the half. The beneficial effect was 
greatest for high risk women, and those with low calcium intake. 
 
3. Fish Oil Supplementation: 
In 2006 makrides & olatsdottir & collegues and oslin (2000) 
fond that there was no benefit with fish oil supplementation. 
 
4. Anti – Oxidiants: 
Naturally occurring anti oxidants are vitamin C & E. Reduction 
in these anti- oxidants are associated with increased risk of GHT 
(rajimaters & associates 2004). Thus supplementation of anti – 
oxidants improves the oxidative property of women , who has increase 
risk of GHT. But studies ( poston 2006, rumbold 2006) revealed that 
this anti- oxidants will not reduce the risk of pre eclampsia. 
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5. Anti Thrombotic Agent: 
6. Low Dose Aspirin: 
In 1986 wallenburg and associates revealed that daily oral 
dosage of 50 -150 mg of aspirin inhibits thromboxane A2 synthesis, it 
reduce the relative risk of GHT by 10%. 
 
7. Low Dose Aspirin & Heparin: 
High incidence of thrombotic lesion in placenta was found in 
GHT patient. In 2006 sergis and associates found that low dose aspirin 
with low molecular heparin improve the pregnancy outcome in GHT 
patient when its compare with low dose aspirin alone. 
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OBJECTIVES 
   
1. To test the hypothesis that women with high serum beta HCG & 
lipid profile in early second trimester have risk of developing 
hypertensive disorder of pregnancy 
2.  To identify the “at risk” women earlier may help in taking timely 
prevention and curative management and to prevent complications 
associated with GHT. 
3. To study the strength of association between the elevated beta 
HCG & lipid profile with GHT 
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MATERIALS AND  METHODS 
 
 This was a prospective study, conducted in OP population at Raja 
Mirasudar Hospital, Thanjavur from Sep 2014-  aug 2015. Total  no of 
100 pregnant women who attended antenatal clinic of department of 
O&G at RMH Thanjavur were included.  All the patient were  screened 
for serum beta HCG & lipid profile in early second trimester between 
(14-20 wks) ,to be followed up till their delivery. The study groups 
involved both primi & multi gravida. They were selected on the basis of 
simple random sampling.  
Comparative study of serum beta HCG and lipid profile performed 
between those who remain normotensive and those who develop GHT. 
GHT was defined as systolic blood pressure more than 140mmmhg and 
diastolic blood pressure more than 90mmhg occurring on two (or) more 
occasions after 20 wks of gestation recorded 6 hours apart.  Preeclampsia 
is defined as gestational hypertension and proteinuria of at least  (2+) / 
1g/dl on dip stick (or) 24 hrs urinary protein excretion > 0.3 g. 
Fasting venous blood sample (3ml) was collected and tests were 
carried out on the same day. Estimation of serum beta HCG  level was 
done by enzyme linked immune absorbant assay. The quantitative 
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determination of chorionic gonodotropin in human serum was carried out 
by micro immune enzymatic assay with kits obtained from monokind Inc 
osta mosa. 
Serum lipid profile estimation was done by enzymatic calorimetric 
test with lipid clearing factor ( LCF) using kits.  LDL cholesterol & 
VLDL cholesterol valves in mg/dl are indirectly measured . The cases 
were followed up regularly in the antenatal OPD till delivery. All the 
detailed data were collected from the delivery log book. Data was 
analysed statistically. The study group participated voluntarily in this 
study and each of them gave an informed consent. This study was 
approved by ethical and research committee of Thanjavur medical 
college. 
 
INCLUSION CRITERIA: 
1. Patient with previous history of GHT 
2. AN mother in gestational age of ( 14-20 wks) 
 
EXCLUSION CRITERIA: 
1. Hypertension diagnosed before 20 wks of gestation 
2. Diabetics 
3. Multiple pregnancy 
4. Molar pregnancy 
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5. Hypothyroidism 
6. USG proven fetal congenital malformation 
7. H/O  hypercholesterolemia 
 
CUT OFF VALVES 
  NORMAL ABNORMAL 
Beta HCGmIU/l 20000-25000 >250000 
TG mg/dl < 200 >200 
VLDL mg/dl < 40 >40 
TC mg/dl <200 >200 
LDL mg/dl < 130 >130 
HDL mg/dl >65 <65 
BP mmofHg 110-138/72-88 140/90 
 
METHOD OF COLLECTION OF SAMPLE: 
Samples were drawn after an overnight fasting from the antecubital 
vein 3 ml whole blood was collected in red capped vaccum tube 
containing clot activator and left at room temperature to clot for half an 
hour. Serum was separated by centrifugation at 1200rpm and analysed 
using Siemens dimension . 
 
RMH - OPD 
 
 
DEPARTMENT OF BIOCHEMISTRY 
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METHODOLOGY OF LIPID PARAMETERS: 
                         Parameters                Methodology 
Total cholesterol CE/CO/HPO 
HDL cholesterol Accelerator selective detergent 
LDL cholesterol Detergent / CE/ CO/POD 
Triglycerides LPL/GK/GPO/POD 
 
ESTIMATION OF TOTAL CHOLESTEROL: 
Principle:  
                Cholesterol esterase  catalysethe hydrolysis of cholesterol esters 
to produce free cholesterol which, along with pre existing free cholesterol 
oxidase to form cholest 4-ene-3one and hydrogen peroxide. In the 
presence of hydrogen peroxidase ( HPO).. The hydrogen peroxide thus 
formed is used to oxidize N, N diethyl aniline- HCL / 4 amino triptyline 
is directly proportional to the total cholesterol concentration and is 
measured using a polychromatic (453,540,700 nm) end point technique. 
           
  Chosterol estors    ------------------- cholesterol + fatty acid  
  
Cholesterol + O2 ----------------------   cholest 4-ene-3one + H2O2 
 
Cholesterol oxidase 
Cholesterol esterase 
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 2H2O2 +DEA.HCL/AAP---------------4 H2O + oxidized DEA. HCL/AAP 
          
Potassium oxalate/ sodium fluoride can decrease cholesterol results 
an average of 12%. li heparin can depress cholesterol results by an 
average of 4gm/ dl t a level of 200 mg/ dl 
ESTIMATION OF HDL CHOLESTEROL: 
Principle:  
                The HDL cholesterol assay is homogenous method for directly 
measuring HDL – C levels without the need for off line pre treatment (or) 
centrifugation steps 
                  Accelerator selective detergent methodology 
HDL,LDL,VLDL,Chylomicrons--------     LDL,VLDL,chylomicrons. 
              HDL ------------- HDL disrupted 
              HDL cholesterol ---------------------- cholesterone + H2O2 
              H2O2 + DSBM+4-AAP ------------ colour department 
                         (Wavelength 600nm & 700nm)   
ESTIMATION OF LDL CHOLESTEROL: 
         Nonsoluble LDL-C, VDRL –C ---------------- soluble non- LDL- C 
         Soluble non-LDL-C ------------non colour forming 
         Non soluble LDL-C ------- soluble  LDL-C 
         Soluble LDL + O2-----------cholestenone + H2O2 
         H2O2+ DSBMT+ 4-AA------------ colour development 
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ESTIMATION OF TRIGLYCERIDES: 
             Triglycerides----------------- glycerol+ fattyacids 
             Glycerol+ ATP ---------------glycerol -3- phosphate + ADP 
             Glycerol-3-phosphate+O2 ----- dihydroxyacetone phosphate Po4 
             2H2O2+aminoantipyline------------quinoneimine+ HCL+ 4 H2O 
                                    ( wavelength  510nm & 700 nm) 
BETA HCG: 
               The HCG quantitative  test is also known as quantitative serial 
beta HCG, Repeat quantitative beta HCG, beta HCG blood test and 
quantitative blood pregnancy test. 
              Quantitative measurement of beta HCG was done by ELISA 
technique. Blood sample were collected with all aseptic precautions. 
Serum was separated by centrifugation. All reagents were brought to 
room temperature. 25 µL of serum samples were put into microplate well. 
100µL of enzyme reagent (β HCG) were added to all wells, incubated and 
contents were discarded.100 µ L of working substrate solution was added 
and incubated. Then 50µ L of stop solution was added and absorbance in 
each well was read by ELISA reader. 
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STATISTICAL ANALYSIS 
 
Data was expressed in terms of mean +/- SD. Chi square test was 
applied to estimate the difference between positive groups. Unpaired ‘t’ 
test was used to study the changes in the beta HCG  and lipid profile 
values. 
 
        P value > 0.05 was taken as non significant 
        P value < 0.05 was taken as significant  
        P value < 0.01 was taken as highly significant 
        P value < 0.001 was taken as  very highly significant 
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RESULTS 
 
The results obtained from this present study  were categorised 
according to their initial beta HCG & lipid profile level. 
Those who had elevated beta HCG & LIPID PROFILES 
categorised in study group. 
 
      Following parameters are analysed: 
1. Serum β HCG 
2. TG 
3. HDL 
4. VLDL 
5. LDL 
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              TABLE :1               AGE GROUP (years) 
 
GROUPS 18-20 21-25 26-30 >30 
GHT 5 10 23 4 
NORMOTENSIVE 11 13 29 5 
TOTAL 26 23 52 9 
 
 
 
           The age group of the subject was between 18-30 years. The mean 
age and standard deviation in GHT was 24.48 ± 2.08 years and in 
normotensive it was 23.65±2.47 years. There was no statistical 
difference. 
 
 
GHT
NORMOTENSIVE
Column1
0
5
10
15
20
25
30
18-20 
yrs
20-25 
yrs
25-30 
yrs
>30 
yrs
GHT
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                                   TABLE 2:    GRAVIDA 
GROUPS PRIMI G2 G3 G4 
NEGATIVE 15 13 13 4 
 Beta HCG 
(+) Ve 
5 2 12 1 
Lipid profile 
(+) Ve 
4 13 1 0 
Both (+)Ve 15 11 10 1 
Total 39 29 26 6 
 
 
 
PRIMI
G2
G3
G4
0
2
4
6
8
10
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16
NEGATIVE
BETA HCG 
(+)
LIPID 
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BOTH (+)
PRIMI
G2
G3
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                             TABLE 3  :       GESTATIONAL AGE 
             GA 14-16 wks 17-18 wks 19-20 wks 
Negative 17 16 12 
Beta hcg (+) 6 3 1 
Lipid profile 
(+) 
4 2 2 
Both (+) 17 13 7 
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TABLE 4 :  BLOOD PRESSURE 
 
 
 
 
 
 
  
GROUP 
Mean SBP with SD 
(mmhg) 
MeanDBP with SD 
(mmhg) 
CASES 
143.76±5.84 
 
90.28± 5.53 
CONTROLS 115.8±9.02 81.2±3.84 
 
Showing MEAN SBP ± SD of blood pressure  in the study group was 
143.76±5.84. MEAN DBP ±SD of blood pressure was 90.28±5.53 
0 10 20 30 40 50 60 70
Less than 140/90
More than 140/90
Frequency
Frequency
BP Frequency 
less than 140 /90 58 
more than 140/90 42 
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                          TABLE 5 :  BETA HCG                   
                   HCG    FREQUENCY 
LESS THAN 25000 52 
MORE THAN 25000 48 
                            
                         
  52% had beta hcg less than 25000 & 48% had beta hcg more than 
25000. 
 
 
 
 
 
LESS THAN 25000
MORE THAN 25000
46
47
48
49
50
51
52
Frequency
Frequency
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TABLE 6: CORRELATION BETWEEN HCG & BP 
HCG 
BP 
SI 
less than 140 /90 more than 140/90 
Less than 25000 42 10 x2= 23.056 
df = 1 
P< 0.01 
Significant   
More than 25000 16 32 
  
           Among 100 women,52 of them had beta hcg less than 25000, 
among them only 10 women developed GHT. Among the 48 women who 
had serum beta hcg more than 25000, 16 women did not develop GHT. 
32 developed GHT. Statistically significant relationship exist between 
elevated serum beta hcg and development of GHT.  
              
Sensitivity  65% 
Specificity 80% 
Positive predictive value 86% 
Negative predictive value 74% 
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                 TABLE 7:      TRIGLYCERIDE VALUE 
               TGL FREQUENCY 
LESS THAN 200 mg/dl    66 
More than 200 mg/dl    34 
 
 
      34% had triglycerides level more than 200 mg/dl. 66% had 
triglycerides level less than 200 mg/ dl. 
  
  
0
10
20
30
40
50
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TABLE 8: CORRELATION BETWEEN TGL & BP 
TGL 
BP 
Total 
less than 140 /90 more than 140/90 
Less than 200 51 15 x2= 29.599 
df = 1 
P< 0.01 
Significant   
More than 200 7 27 
 
            Among 100 women 66 of them had triglycerides level less 
than 200 mg/dl, among them only 15 women developed GHT. Among 
the 34 women who had triglycerides more than 200 mg/dl, 7 did not 
develop GHT. 27 developed GHT. Statistical significant relationship 
exists between triglycerides and development of GHT. 
 
 
 
Sensitivity 78% 
Specificity 98% 
Positive predictive value 97% 
Negative predictive value 85% 
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TABLE 9  :      HDL VALUE 
 
HDL Frequency 
More than 65mg/dl 65 
Less than 65mg/dl 35 
 
 
               35%  had HDL less than 35% and 65% had elevated HDL 
 
 
 
 
 
0
10
20
30
40
50
60
70
More than 65mg/dl
Less than 65mg/dl
Frequency
Frequency
  
 
71 
 
 
 
         TABLE 10. CORRELATION BETWEEN HDL & BP 
HDL 
BP 
Total 
less than 140 /90 more than 140/90 
more than  65 55 10 x2= 54.005 
df = 1 
P< 0.01 
Significant   
less than 65 3 32 
 
                  Among 100 women 65 of them had HDL level more than 65 
mg/dl , among them only 10 of women developed GHT. Among the 35 
women who had HDL less than 65 mg/dl, 3 did not develop GHT. 32 
developed GHT. Statistical significant relationship exists between HDL 
and development of GHT. 
 
Sensitivity 69% 
Specificity 90% 
Positive predictive value 86% 
Negative predictive value 77% 
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TABLE 11     VLDL VALUE 
 
 
 
 
 
 
 
 
 
              37 % had elevated VLDL level more than 40 mg/ dl. 63% had 
VLDL level less than 40 mg/dl. 
 
 
0 10 20 30 40 50 60 70
Less than 40 mg/dl
More than 40 mg/dl
Frequency
Frequency
VLDL FREQUENCY 
Less than 40 mg/dl 63 
More than 40 mg/dl 37 
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           TABLE 12: CORRELATION BETWEEN VLDL & BP 
VLDL 
BP 
Total 
less than 140 /90 more than 140/90 
less than 40 53 10 x2= 47.713 
df = 1 
P< 0.01 
Significant 
more than 40 5 32 
                            
           Among 100 women 53 of them had VLDL level less than 40 mg/dl   
among them only 10 of women developed GHT. Among the 35 women 
who had VLDL more than 40 mg/dl, 5 did not develop GHT. 32 
developed GHT. Statistically significant relationship exists between 
VLDL and development of GHT. 
       
 
Sensitivity 69% 
Specificity 92% 
Positive predictive value 88% 
Negative predictive value 78% 
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TABLE 13: LDL VALUE 
 
 
 
 
 
 
      61 % had LDL level less than 130 mg/dl. 39% had LDL level more 
than 130 mg/dl 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Less than 130 mg/dl More than 130 mg/dl
Frequency
Frequency
LDL frequency 
Less than 130 mg/dl 61 
More than 130 mg/dl 39 
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        TABLE 14 :   CORRELATION BETWEEN LDL & BP 
LDL 
BP 
SI 
less than 140 /90 more than 140/90 
less than 130 55 6 x2= 66.424 
df = 1 
P< 0.01 
Significant   
more than 130 3 36 
                              
 
            Among 100 women 61 of them had LDL level less than 130 mg/dl   
among them only 6 of women developed GHT. Among the 39 women 
who had  LDL more than 130 mg/dl, 3 did not develop GHT. 36 
developed GHT. Statistically significant relationship exists between 
VLDL and development of GHT. 
 
Sensitivity 78% 
Specificity 98% 
Positive predictive value 97% 
Negative predictive value 85% 
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                                              TABLE 15 
 
           CORRELATION BETWEEN β HCG & LIPID   PROFILE 
 
 
Βeta 
HCG 
TGL HDL VLDL LDL 
Sensitivity 65% 78% 69% 69% 78% 
Specificity 80% 98% 90% 92% 98% 
Positive predictive 
value 
86% 97% 86% 88% 97% 
Negative predictive 
value 
74% 85% 77% 78% 85% 
 
 
                          TGL & LDL had high specificity (98%)  and high 
positive predictive value (97%)  than other parameters. Among them 
TGL & LDL can be used as a good predicting tool to identify those who 
developing GHT later. 
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TABLE 16 
STRENGTH OF ASSOCIATION BETWEEN BETA HCG& LIPID 
PROFILE WITH GHT 
 
     PARAMETERS RELATIVE RISK (%) 
BETA HCG 3.2% 
TGL 1.8% 
HDL 3.2% 
LDL 6% 
VLDL 3.2% 
 
 
                  For lipid profile , for one unit increase in LDL, pregnant 
women had 6% probability of developing GHT. For one unit increase in 
VLDL & Triglycerides & BETA HCG there is 3.2% and 1.8% and 3.2% 
increased change of developing GHT. On the contrary, with one unit 
increase in HDL , the women had 11.4% less chance of developing GHT 
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TABLE 17:  FOLLOW UP STUDY 
 
 
Among this parameter those who had elevated VLDL lipoproteins 
are more prone to develop early onset GHT than others. 
 
 
 
 
 
 
 
 
 
 
 
Positive 
 
Total no 
of GHT 
 
6th 
Month 
7th 
Month 
8th 
Month 
9th 
Month 
β-hcg 48 32 - - 5 27 
HDL 35 32 - - 6 26 
VLDL 37 32 - 4 10 18 
LDL 39 36 - 1 6 29 
TGL 33 27 - - 12 15 
  
4TH MONTH 
SERUM BETA Hcg  ↑ LDL ↑ VLDL ↑ 
 
9TH MONTH  
 BP 140 / 90  
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                                             TABLE 18 :                            
                    MODE OF DELIVERY IN TOTAL POPULATION: 
LN  LSCS  Assisted Expulsion 
Spontaneous Induced Emergency Elective   
34 28 29 7  2 
 
 
 
 
 
 
 
 
       TABLE 19            MODE OF DELIVERY IN GHT PATIENTS: 
LN  LSCS  Assisted Expulsion 
Spontaneous Induced Emergency Elective   
10 16 11 3 0 2 
      
In GHT induction of labour was more common. As other causes of 
induction were not excluded in study, we cannot correlate significantly 
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                                         TABLE 20 
                      MATERNAL COMPLICATION 
                   
COMPLICATION BETA HCG 
(+) 
LIPID 
PROFILE (+) 
BOTH 
Pre eclampsia 0 0 2 
Eclampsia 0 0 1 
HELLP syndrome 0 0 0 
     
          
 
                         Women who had both beta HCG & lipid profile 
abnormalities , increased risk of developing complication than isolated 
abnormalities. 
β Hcg
LIPID PROFILE
BOTH
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
Pre 
eclampsia
Eclampsia
HELLP 
Syndrome
β Hcg
LIPID PROFILE
BOTH
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                                            TABLE 21 
                                  FETAL COMPLICATION 
complication Beta HCG (+) Lipid profile (+) Both (+) 
IUGR 1 0 2 
PRETERM 0 0 1 
RDS 2 1 6 
 
 
 
Among fetal complication RDS was most common in GHT 
women. Women who had both beta HCG & lipid profile abnormalities 
had increased risk of having IUGR.  
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DISCUSSION 
                Pregnancy is the most important period in women’s life, but it 
can be dangerous also. Hypertension and proteinuria are the important 
complications of pregnancy. Abnormal placentation is the one of the 
important pathology for the development of GHT. Because of abnormal 
placentation there may be increased synthesis of beta HCG.  
                 There may be a dysregulation of lipoprotein lipase in GHT 
prone women, that causes elevated plasma lipid and lipoprotein levels, 
may induce endothelial dysfunction secondary to oxidative stress. 
Endothelial dysfunction is the prominent pathology, usually occurs in 
early trimester (8-18weeks) but signs and symptoms occur in late 
trimester. 
          In this study serum beta HCG estimated in early second trimester, 
women with elevated levels, categorized under high risk group. So it is 
easy to identify the high risk women and kept under regular follow up. It 
is help in preventing development of complication in GHT. 
            Study conducted in OP population in Raja Mirasudar Hoapital, 
Thanjavur Medical College,  Thanjavur. It is a prospective study, 
conducted on 100 pregnant women who attended the antenatal OPD. All 
the patients screened for BETA HCG & lipid profile in early second 
trimester between (14-20 weeks) and followed up till their delivery. 
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              Normally GHT is  more common in teenage pregnancies. In our 
study most of the GHT patient within the age group between 26-30 years 
with standard deviation of 24.48 ± 2.08 years. 
                Normally GHT more common in primi gravid, in our study also 
more number of GHT cases were primi gravid. 
            Blood pressure (140/90 mm of Hg) was used as a cut off for GHT. 
58% had less than that above value, 42% had blood pressure more than 
140/90 mm of Hg. GHT cases had mean SBP with SD of about 
143.76±5.84 and mean DBP with SD was 90.28± 5.53. 
            Regarding beta HCG 25000 mIU/l used as a cut off value. In 100 
population 52% had less than 25000 beta HCG & 48% had more than 
25000 beta HCG value. 
                  In our study among 100 women, 48 of them had 
elevated beta HCG value, among them 32 of them developed GHT. 52 of 
them had beta HCG less than 25000, among them only 10 women 
developed GHT. With that value statistical significant relationship exist 
between elevated beta HCG and development of GHT with p value 
<0.01. 
 This is in accordance with the study done by the Yaron et al21 & 
Ellis p et al & Hijam danina et al , they also showed that there is 
significant increase in serum beta HCG in early second trimester and 
development of GHT .  
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 In our study beta HCG showed 80% specificity & 86% positive 
predicting value. Similar results were obtained in Yaron et al. They 
shown that beta HCG had high positive predictive value of about 88% 
.They concluded with that predictive value, serum beta HCG can be used 
as a predictor for GHT. 
 In our study strength of association between beta HCG and GHT 
is about 3.2%. In Vidyabati et al 25(2003) they proven that, for one unit 
increase in the beta HCG,  pregnant  women had 3.7% increasing chance 
of GHT. 
 In our study among 100 women, 34 of them had elevated 
triglycerides value, among them 22 of them developed GHT. 66 of them 
had triglycerides less than 200, among them only 15 women developed 
GHT. With that value statistical significant relationship exist between 
elevated triglycerides and development of GHT with p value <0.01. 
In Clause T18, (1998) & Djurovic et al21 (2001) found that 
dyslipidemia seems to be more efficient marker in predicting GHT at 
early second trimester with statistical significant (p <0.05). In Clause T 
did a study in 1998 in100 pregnant women, in that 54 % had elevated 
triglycerides, among them 48% developed GHT with statistical 
significant value. 
   In our study elevated triglycerides value had 98% high specificity 
0& 97% positive predictive value. In Pouta et al (2000) found that 
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significant correlation between the elevated triglycerides and 
development of GHT with 96% specificity. Clausen et al26 concluded that 
hypertriglycedemic dyslipidemia before 20 weeks of gestation had 
increased relationship with early onset GHT . They had a significant p 
value of about <0.01 and high positive predictive value (92%)  
 In our study strength of association between triglycerides and 
GHT is about 1.8%. In Vidyabati et al25 (2003) they proven that, for every 
one unit increase in the triglycerides, pregnant women had 2.0% 
increasing chance of GHT.  
In our study among 100 women, 35 of them had reduced HDL 
value, among them 32 of them developed GHT. 65 of them had HDL 
more than 65, among them only 10 women developed GHT. With that 
value statistical significant relationship exist between reduced HDL and 
development of  GHT with p value <0.01. 
Turpin et al 42(2001) did a study in 150 women & found that 
women who had elevated HDL value, have a reduce risk of GHT. Islam 
et al (1998) revealed that women with reduced HDL value more prone to 
develop GHT with a statistical significant value (p<0.05). 
In our study HDL had 90% specificity & 86% positive predictive 
value. Similar results were obtained by Lima et al (1999) with 92% 
specificity & 88% positive predictive value. 
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In our study strength of association between increased HDL and 
preventing GHT is about 3.2%. In Vidyabati et al25 (2003) they prove 
that, for one unit increase in the HDL, a pregnant women had 3.7% less 
chance of GHT. 
 In our study among 100 women, 37 of them had elevated VLDL 
value, in which 32 of them developed GHT. 63 of them had VLDL less 
than 40, among them only 10 women developed GHT. With that value 
statistical significant relationship exist between elevated triglycerides and 
development of GHT with p value <0.01. 
In 1998 Taital mikic researchers & De et al 44(2004) they found 
that there is a significant rise in VLDL value in GHT women. They did 
Meta analysis study in 2004; they concluded that elevated VLDL is a 
common finding in GHT women, in all study. They had a statistical 
significant value between elevated VLDL and GHT women (p<0.001). 
In our study VLDL had 92% specificity, this is supported by FranZ 
H, Wender D (2002), they proven that elevated VLDL had 90%  
specificity & positive predictive value, with that they agreed that VLDL  
is the one of good predictor for GHT.  
In our study among 100 women, 39 of them had elevated LDL 
value, among them 36 of them developed GHT. 61 of them had LDL less 
than 130, among them only 6 women developed GHT. With that value 
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statistical significant relationship exist between elevated triglycerides and 
development of  GHT with p value <0.01. 
In 2005 Cekman et al28 did a study in 150 pregnant women. In that 
96 of them had elevated LDL more than 130mg/dl, among them 78 
developed GHT. 54 of them had normal LDL value. In this only 10 
developed GHT. With this result they proved very highly significant 
relationship between LDL and GHT.  
 In our study strength of association between LDL& VLDL with 
GHT was 6% & 3.2% respectively. Wakatsuki et al 40(2001) had proven 
that similar association between the LDL& VLDL with GHT . For every 
one unit increase in LDL & VLDL 6.8% & 4.5% there is  increase risk of 
developing GHT in pregnant women respectively. 
Induction of labour is more common in GHT. This also happened 
in our study, but there is no statistical significance was obtained in our 
study. This may be due to small sample size, variation in  the gravida in 
total study population. 
In our study 2 of them had severe pre eclampsia & 1 of them had 
eclampsia. Women with severe preeclampsia had high levels both beta 
HCG & lipid profile particularly TGs. This  was supported by Turpin et 
al42 in the year 2003 made a study with lipid changes in pregnant women 
associated with the development of gestational hypertension. They 
concluded that women with elevated triglycerides level ( > 3.0 MoM) had 
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increased chances (17% ) of developing GHT and early onset severe pre 
eclampsia. 
  
• In our study  fetal complications like IUGR and RDS are more 
common in GHT patients. This supported by Gonen et al & 
Valiient et al , they found that there is increase risk of development 
of IUGR & RDS more common in GHT than control groups.  In 
the year 2003Vallient et al 40demonstrated that free beta HCG was 
a marker of high risk for GHT & associated with small for 
gestational age .They did a study in 192 pregnant women. Women 
with beta HCG > 3.5 MOM is taken as study group. In 192, 87 of 
them had elevated beta HCG. In the study group 24 of them 
developed GHT in third trimester. In which 12 of them had IUGR 
baby .They also found that women with elevated serum beta HCG 
were associated with increased risk of IUGR baby with statistical 
significance value (p <0.01). 
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CONCLUSION 
                 Even in this era of advanced medical knowledge what we don’t 
know far outweighs what we know. The case is no different with GHT, a 
leading killer of mothers worldwide. Despite one of the top causes for 
maternal mortality and morbidity very little is known about its aetiology. 
Many studies were conducted to determine to exact sequence of events 
behind its presentation. Recent studies have found out that the clinical 
manifestation of GHT is proceeded way back by biochemical and 
pathological changes in the body. This is the reason why all modes of 
treatment except delivery are only palliative. 
If we can detect these changes before hand a major share of 
maternal mortality can be prevented. The level of beta HCG and lipid 
profile are two factors strongly associated with development of GHT. 
These can be used as “POWERFUL PREDICTIVE TOOL” for 
obstetrician for early identification and expert management. Then close 
monitoring of maternal and fetal status of identified cases can be done in 
tertiary care centre like our institution resulting in a good maternal 
and perinatal care 
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SUMMARY 
A Study of serum beta HCG and lipid profile in a early second 
trimester is a predictor of GHT. 
   This study was done at Thanjavur medical college , Thanjavur. 
 In total 100 women, initial beta HCG and lipid profile evaluation 
was done in early second trimester. 
 Those who have elevated value taken as cases and others included 
in control population. 
 Elevated values in cases were compared with GHT population,  
showed statistically significant (p<0.01) 
The present study showed  elevated beta HCG and lipid profile in 
GHT, suggesting the role of abnormal placentation and endothelial 
dysfunction  due to lipoprotein lipase in the aetiology of GHT , though 
the exact mechanism remains to be elucidated.  
The strength of association between these factors and GHT are 
very much significant. So it can be used as a predictor of GHT. These 
factors are very useful in the earlier period of gestation in the screening of 
GHT. 
In this study there is no maternal mortality, CVA, severe acute 
renal failure, HELLP syndrome. With the regular monitoring I had 2 
cases of severe pre eclampsia and one  eclampsia.  Regarding the 
perinatal outcome incidence of IUGR and RDS are more common in 
GHT. 
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ANNEXURE-1 
 
CONSENT FORM 
 
 
I   …………………………..exercising my free power of choice 
here by give consent to participate in the study conducted by 
Dr.V.MUNIRA Post graduate in Department of Obstetrics and 
Gynaecology, Govt. Raja Mirasudhar Hospital, Thanjavur – 613001. I 
have been given full explanation in my own language about the purpose 
of study and the investigations for any complications with co-morbid 
conditions. 
 
       Signature of the participant 
 
Place: 
Date: 
 
 
 
  
 
 
 
                                        PROFORMA 
 
NAME: 
AGE:  
OP NO: 
DIAGNOSIS: 
PAST H/O: DM/ HT/TB/EPILEPTIC/HEART DISEASE/THYROID 
PROBLEM 
FAMILY H/O 
OBSTETRIC H/O: 
         Mode of delivery: FTNVD/ LSCS 
          Birth weight: 
          Postnatal events: 
  GENERAL EXAMINATION: 
                      HT:                  WT :                    BMI:                  BP: 
                         Anemic/ PE/ icteric/ lymphadenopathy 
         P/A: 
         U/A: 
         SERUM BETA HCG: 
         LIPID PROFILE: 
1. TGL 
2. HDL 
3. LDL 
4. VLDL 
 
 
                    
  
 
 
 
 
FOLLOW UP: 
 6th month 7th month 8th month 9th month 
PE     
U/A     
BP     
 
 
MODE OF DELIVERY: 
        FTNVD: spontaneous/ induced 
         FTLSCS: elective/emergency 
         ASSISTED: 
SPONTANEOUS EXPULSION: 
 
MATERNAL COMPLICATION: 
1. Severe pre eclampsia: 
2. HELLP syndrome: 
3. Eclampsia: 
 
FETAL COMPLICATION: 
1. IUGR: 
2. RDS: 
3. LBW 
           
           
MOD BW PN 
events A PE I HB UA HOL LOL VLDL
1 JASMINE DELPHI 30 G3P1L1A1 16 _ LSCS 3 _ N N N 110/70 10 _ 16 26000 > > N N
2 ABINAYA 20 PRIMI 14 GDM _ _ _ N N N 120/60 9.6 _ 14 28000 > < N N
3 MARIYAMMAL 26 G2P1L1 14 _ _ _ _ N N N 110/70 9.5 _ 14 21000 N N N N
4 RADHALAKSHMI 33 G3P2L2 15 _ 2FTNVD 2.5/2.5 _ N yes N 120/70 10 _ 14 31000 > < > N
5 KARTHIKA 30 G2A1 15 _ 0 _ _ N N N 110/70 9.8 _ 14 23000 N N N N
6 AROKIYASHEELA 26 G2P1L1 17 _ FTNVD _ _ N N N 120/60 9.6 _ 16 25600 > > N N
7 RUTHNISHA 25 PRIMI 18 _ 0 _ _ N N N 110/70 9.5 _ 18 31000 N N N N
8 LAKSHMI 28 G3P2L2 19 _ 1FTND/1LSCS 2.8/2.6 _ N N N 120/60 9.7 _ 18 26000 < > N >
9 MAHALAKSHMI 27 G3P1L1A1 19 _ FTNVD _ _ MA N N 110/80 9.5 _ 18 22000 N N N N
10 RANI 27 G3P1L1A1 14 PIH 0 _ _ N N N 100/70 9.5 _ 14 21000 > < > N
11 DEVI 19 PRIMI 14 _ 0 _ _ N N N 110/80 9.3 _ 14 26000 N N N N
12 SUSEELA 21 G2A1 20 _ 0 _ _ N N N 110/60 9.4 _ 20 23000 N N N N
13 SUTHANNATHIYA 29 G3P2L2 20 _ 2FTNVD 2.6/2.5 _ N N N 120/80 9.5 _ 20 28000 > N N <
14 DILSATHBEGUM 28 PRIMI 15 _ 0 _ _ N N N 110/70 9.5 _ 14 23000 N N N N
15 ANJUPOON 26 G2P1L1 17 PIH LSCS _ _ N N N 110/60 9.6 _ 16 26000 > < N >
16 ASHIFAHANIFER 26 G2A1 18 _ 0 _ _ N N N 100/60 9.4 _ 18 23000 N N N N
17 LAKSHMIPRIYA 29 G3P1L1A1 16 _ 0 2.5 _ N N N 110/70 9.6 _ 18 24660 N N N N
18 SHANMUGALAKSHMI 23 PRIMI 16 _ _ _ _ N N N 120/60 9.3 _ 16 23000 > < N N
19 THAHIRADILFAR 23 PRIMI 16 _ _ _ _ N N N 110/70 9.5 _ 16 30000 > < N N
20 PANIMALAR 25 G2P1L1 14 _ LSCS 3 _ N N N 100/60 9.5 _ 14 21500 N N N N
21 VASUKI 28 G2A1 14 _ _ _ _ N N N 120/80 10 _ 14 21000 N N N N
22 DHARANIJAYASHREE 26 PRIMI 14 _ _ _ _ N N N 110/70 9.8 _ 14 21500 N N N N
23 MALATHI 30 G4P1L1A2 15 PIH FTNVD 2.614 _ N N N 120/80 9.6 _ 14 31000 > < N N
S. No Name Age DP No. obstetric GA Past H/O
Previous Obstric H/O General Lab TOTAL CHOLESTEROLBP P/A SemB.hu TC
MOD BW PN 
events A PE I HB UA HOL LOL VLDL
S. No Name Age DP No. obstetric GA Past H/O
Previous Obstric H/O General Lab TOTAL CHOLESTEROLBP P/A SemB.hu TC
24 NALINI 21 PRIMI 16 _ _ _ _ MA N N 110/70 9.6 _ 16 22000 N N N N
25 SUNANDHA 24 G2A1 18 _ _ _ _ N N N 120/80 9.6 _ 18 26000 N N N N
26 SELVAPRIYA 21 PRIMI 16 _ _ _ _ N N N 110/70 9.5 _ 16 24000 N N N N
27 DEEPALAKSHMI 26 G2P1L1 18 _ FTNVD 2.5 _ N YES N 120/60 9.6 _ 18 28000 N N N N
28 KANJANA 23 PRIMI 20 _ _ _ _ N N N 100/60 9.5 _ 18 23000 > N > N
29 KAVITHA 25 G3P1L1A1 20 _ FTNVD 3 _ N N N 110/70 9.4 _ 20 24000 N N N N
30 VANITHA 19 PRIMI 18 _ _ _ _ N N N 120/80 9.6 _ 18 28000 N N N N
31 YOGALAKSHMI 19 PRIMI 16 _ _ _ _ N N N 110/70 9.7 _ 16 23000 > > N N
32 AMUDHA 24 G2P1L1 17 _ FTLSCS 2.8 _ N N N 120/80 9.5 _ 16 23000 N N N N
33 MALLIGA 20 PRIMI 15 _ _ _ _ N N N 110/70 9.4 _ 14 22000 N > N N
34 MARAGATHAM 21 PRIMI 14 _ _ _ _ N N N 120/70 9.6 _ 14 21000 N N N N
35 SATHYAVANI 21 G2A1 18 _ _ _ _ N N N 110/80 9.7 _ 14 22000 N N N >
36 AMIRTHAVALLI 26 G3P1L1A1 19 _ FTNVD 2.9 _ N N N 100/60 9.5 _ 18 26000 N N N N
37 SARASWATHY 30 G3P2L2 16 2FTND 2.5,2.5 N N N 110/70 9.4 _ 16 23000 > < N N
38 SHANMUGAM 26 G2A1 14 _ _ _ _ N N N 110/70 9.6 _ 14 22000 N N N N
39 JEYAPRADHA 26 PRIMI 15 _ _ _ N N N 110/60 9.6 _ 14 22000 N N N N
40 MARIYAMMAL 30 G4P1LIA2 17 _ FTLSCS 3 N N N 110/70 9.4 _ 16 24000 < > N N
41 ABIRAMI 33 G3P2L2 17 _ 1LSCS 1FTNVD 3, 2.2 N N N 100/60 10 _ 16 25500 N N N N
42 KOLANJIYAM 30 G3P1L1A1 19 _ 1FTNVD 3 MA N N 120/70 10 _ 18 25500 N N N N
43 KOKILA 19 PRIMI 20 _ _ _ N N N 110/70 10 _ 20 26000 > < > N
44 GOMATHY 21 G2P1L1 19 _ 1LSCS 2.4 N N N 120/80 10.7 _ 18 24000 N N N N
45 SHANTHI 28 G3P2L2 18 _ 2 LSCS 2.6,2.9 N N N 110/70 10.5 _ 18 23300 N N N N
46 KUSHPOO 22 PRIMI 14 _ _ _ N N N 120/70 10.8 _ 14 27000 > > > N
MOD BW PN 
events A PE I HB UA HOL LOL VLDL
S. No Name Age DP No. obstetric GA Past H/O
Previous Obstric H/O General Lab TOTAL CHOLESTEROLBP P/A SemB.hu TC
47 JHANANI 26 G2A1 20 _ _ _ N N N 110/70 9 _ 20 25000 N N N N
48 JEYASHREE 28 G2P1L1 14 _ FTNVD 2.7 N N N 100/60 9.6 _ 14 23400 N N N N
49 DHIVYAPRIYA 30 G3P1L1A1 15 _ FTNVD 2.9 N N N 120/70 9.7 _ 14 24300 > < N N
50 BABYNISHA 20 PRIMI 15 _ _ _ N _ N 120/60 9.8 _ 14 28000 N N N N
51 DURGALAKSHMI 28 G3P1L1A1 18 _ FTNVD 2.6 N N N 110/70 9.6 _ 18 21000 N N N N
52 JEMIR FATHIMA 26 G2A1 19 APPENDIX_ _ N N N 100/70 9.6 _ 18 22500 N N N N
53 BRISILA ROSELIN MARY 29 G3P2L2 17 _ 2 LSCS _ N N N 120/80 9.5 _ 16 23000 N N N N
54 ALAGUPRIYA 22 G2A1 17 _ _ _ N N N 110/70 9.4 _ 16 26000 > > N N
55 AMBIKA 20 PRIMI 16 _ N N N 120/70 9.2 _ 16 26000 > < > N
56 KAVITHA 26 G3P1L1A1 14 _ FTNVD 3 N N N 110/70 9.6 _ 14 21500 N N N N
57 GOMATHY 25 G2A1 16 GDM N N N 120/80 9.4 _ 18 22000 N N N N
58 SHANTHI 31 G3P2L2 15 _ 2 FTNVD 3,3.2 MA N N 110/60 9.6 _ 14 23000 N N N N
59 MANGALAM 22 PRIMI 14 _ N N N 100/60 9.4 _ 14 29000 > < > >
60 SHARMILA DEVI 28 G3P1L1A1 20 _ LSCS 3.6 N N N 120/80 9.6 _ 20 24000 N N N N
61 MALARVIZHI 34 G4P1L1A2 20 _ LSCS 1.8 N N N 120/80 9.4 _ 20 30000 > < > N
62 DURGADEVI 30 G3P2L2 15 _ 2 FTNVD 2,2.2 N N N 110/70 9.6 _ 14 25000 N N N N
63 ANBUSELVI 26 PRIMI 16 _ N N N 120/60 9.8 _ 16 24600 N N N N
64 KALAIARASI 27 G2P1L1 18 _ FTNVD 3 N N N 110/70 9.6 _ 18 26000 > < N N
65 MAGAMAYEE 26 G2A1 17 _ N N N 120/60 9.5 _ 16 24000 N N N N
66 RADHIKA 25 G4P1L1A2 17 _ FTNVD 3 N N N 110/70 9.4 _ 16 23000 N N N N
67 SULTAN NACHAIR 20 PRIMI 19 _ N N N 120/60 9.3 _ 16 20000 > < N N
68 MARY JENNIFER 29 G3P2L1 20 IUD FTNVD 1.9,2.5 N N N 110/80 9.6 _ 20 22000 N N N N
69 ASHA BABY 28 G3P1L1A1 18 _ LSCS 2.5 N N N 120/80 9.4 _ 18 21000 N N N N
MOD BW PN 
events A PE I HB UA HOL LOL VLDL
S. No Name Age DP No. obstetric GA Past H/O
Previous Obstric H/O General Lab TOTAL CHOLESTEROLBP P/A SemB.hu TC
70 PANCHAVARNAM 30 G3P1L1A1 16 _ FTNVD 2.4 N N N 120/70 9.3 _ 16 26000 > > N >
71 KANAGA 19 PRIMI 18 _ N N N 120/80 9.7 _ 18 20000 N N N N
72 PRIYADARSHINI 24 G2P1L1 20 _ FTNVD 3.1 N N N 120/70 9.3 _ 18 25000 > < N N
73 MANGAYARKARASI 26 G2P1L1 20 _ LSCS 3.1 N N N 100/60 9.2 _ 18 23200 N N > N
74 ANITHA 20 PRIMI 20 _ N N N 120/70 9.6 _ 18 26000 N N N N
75 SUNDARI 26 G3P1L1A1 18 _ FTNVD 2.6 N N N 110/60 9.7 _ 18 24000 > < N N
76 NAZRIN BANU 30 G3P2L2 16 _ 2 FTNVD 2.1,2.5 N N N 120/70 9.8 _ 16 24300 N N N N
77 MATILDA 20 PRIMI 17 _ N N N 110/60 9.4 _ 16 25000 N N N N
78 AASAIVALLI 26 G3P1L1A1 19 CVT FTNVD 3 N N N 120/70 9.6 _ 18 23200 > > N N
79 AFREINSITHIHA 27 G2P1L1 19 _ LSCS 3.2 MA N N 120/60 9.6 _ 18 25000 N N N N
80 AARTHI 20 G2A1 15 _ N N N 100/60 9.4 _ 14 30000 > < N N
81 VELANKANNI 26 G2P1L1 18 _ FTNVD 3 N N N 110/70 9.6 _ 16 26000 N N N N
82 ABIRAMI 27 G3P1L1A1 15 _ FTNVD 2.5 N N N 120/80 9.5 _ 14 24000 > > > >
83 KAMALA 30 G4P2L2A1 16 _ FTNVD 2.1,2.3 N N N 110/70 9.4 _ 16 30000 N N N N
84 BARAKATH NISHA 32 G3P2L2 15 GHT FTNVD 2.5,2.5 N N N 120/80 9.7 _ 14 26000 N N N N
85 NIRMALA 30 G2A1 17 _ N N N 120/80 9.4 _ 16 24000 > < N N
86 RANJITHA 21 PRIMI 18 _ N N N 120/80 9.6 _ 18 22300 N N N N
87 PUNITHAVALLI 26 G2P1L1 18 _ LSCS 3 N N N 130/80 9.4 _ 18 26000 N N N N
88 THINGALAVAL 24 PRIMI 15 _ N N N 110/70 9.6 _ 14 25000 N N N N
89 DHARSHINI 21 PRIMI 15 _ N N N 120/80 9.8 _ 14 23000 N N N N
90 DHANYA 20 PRIMI 16 _ N N N 120/80 9.4 _ 16 22000 N N N N
91 KURINJIPOO 26 G2P1L1 18 GDM LSCS 3.5 N N N 120/80 9.8 _ 18 25000 > < N N
92 TAMILARASI 30 G3P1L1A1 16 _ LSCS 3 N N N 110/80 9.4 _ 16 26000 N N N N
MOD BW PN 
events A PE I HB UA HOL LOL VLDL
S. No Name Age DP No. obstetric GA Past H/O
Previous Obstric H/O General Lab TOTAL CHOLESTEROLBP P/A SemB.hu TC
93 RADHIKA 26 PRIMI 16 _ N N N 120/80 9.5 _ 16 25000 N N N N
94 MUTHULAKSHMI 25 G2A1 15 _ N N N 110/70 9.2 _ 14 24000 N N N N
95 MAHALAKSHMI 25 PRIMI 15 _ N N N 120/80 9.6 _ 14 25000 N N N N
96 RAJINISHREE 23 PRIMI 14 _ N N N 110/70 9.4 _ 14 25000 > < > N
97 JASMNE PRABHA 23 G2P1L1 15 PIH FTNVD 2.5 N N N 120/80 9.8 _ 14 28000 N N N N
98 ACQUINES RANI 30 G3P2L2 15 GDM FTNVD 2.6,2.8 N N N 110/70 9.2 _ 14 26000 > < N N
99 ILAKKIYA 28 G3P1L1A1 18 _ LSCS 3.5 N N N 120/80 9.4 _ 16 27000 N N N N
100 RAMYA 21 PRIMI 18 _ N N N 110/70 9.2 _ 16 24500 N N N N
1 JASMINE DELPHI
2 ABINAYA
3 MARIYAMMAL
4 RADHALAKSHMI
5 KARTHIKA
6 AROKIYASHEELA
7 RUTHNISHA
8 LAKSHMI
9 MAHALAKSHMI
10 RANI
11 DEVI
12 SUSEELA
13 SUTHANNATHIYA
14 DILSATHBEGUM
15 ANJUPOON
16 ASHIFAHANIFER
17 LAKSHMIPRIYA
18 SHANMUGALAKSHMI
19 THAHIRADILFAR
20 PANIMALAR
21 VASUKI
22 DHARANIJAYASHREE
23 MALATHI
S. No Name
PE BP UA PE BP U/A PE BP U/A PE BP U/A SPO I El.lscs EM A D assisted PE EC Help IUGR
PRETE
RM RDS
PE 110/70 _ PE 110/70 NIL PE 110/70 NIL PE 130/90 NIL YES
_ 120/80 _ PE 120/80 NIL PE 100/70 NIL PE 140/90 NIL YES YES
_ 110/70 _ _ 120/60 NIL _ 110/70 NIL _ 120/80 _ YES
_ 120/80 _ _ 120/70 NIL PE 120/80 NIL PE 130/90 NIL YES YES
_ 110/70 _ _ 110/70 NIL _ 140/80 NIL _ 110/80 _ YES
_ 110/70 _ _ 110/70 NIL _ 130/80 NIL _ 120/70 _ YES
_ 110/70 _ _ 120/80 NIL _ 120/80 NIL _ 110/80 _ YES
_ 120/80 _ _ 110/70 NIL PE 110/70 NIL PE 130/90 NIL YES YES
_ 110/70 _ _ 120/70 NIL _ 120/80 NIL _ 120/80 _ YES
_ 120/80 _ _ 110/70 NIL PE 110/70 NIL PE 140/90 NIL YES
_ 110/70 _ _ 120/80 NIL _ 120/80 NIL _ 110/70 _ YES
_ 120/80 _ _ 110/70 NIL _ 110/70 NIL _ 120/80 _ YES YES/LATE
_ 110/70 _ _ 110/80 NIL _ 120/80 NIL _ 140/90 NIL YES
_ 120/80 _ _ 110/70 NIL _ 120/80 NIL _ 110/70 _ YES
_ 110/70 _ _ 120/70 NIL PE 140/90 NIL PE 140/90 NIL YES YES
_ 110/80 _ _ 110/80 NIL _ 120/80 NIL _ 110/70 YES YES
_ 110/70 _ _ 110/70 NIL _ 110/70 NIL _ 110/80 _ YES
_ 120/80 _ _ 120/80 NIL PE 120/80 NIL PE 140/90 NIL YES
_ 100/60 _ _ 110/70 _ _ 130/90 NIL PE 140/90 YES YES YES
_ 110/70 _ _ 120/70 _ _ 120/70 NIL _ 120/70 _ YES
_ 110/80 _ _ 120/80 _ _ 110/60 NIL PE 120/70 _ YES YES/MILD
_ 120/80 _ _ 110/70 _ _ 130/80 NIL PE 130/90 YES YES
_ 120/80 _ _ 130/80 NIL _ 130/80 NIL _ 130/90 YES YES YES
Material Fetal complicaiton 6 th Month 7 th Month 8 th Month 9 th Month Mode of delivery Spantanous
S. No Name
24 NALINI
25 SUNANDHA
26 SELVAPRIYA
27 DEEPALAKSHMI
28 KANJANA
29 KAVITHA
30 VANITHA
31 YOGALAKSHMI
32 AMUDHA
33 MALLIGA
34 MARAGATHAM
35 SATHYAVANI
36 AMIRTHAVALLI
37 SARASWATHY
38 SHANMUGAM
39 JEYAPRADHA
40 MARIYAMMAL
41 ABIRAMI
42 KOLANJIYAM
43 KOKILA
44 GOMATHY
45 SHANTHI
46 KUSHPOO
PE BP UA PE BP U/A PE BP U/A PE BP U/A SPO I El.lscs EM A D assisted PE EC Help IUGR
PRETE
RM RDS
Material Fetal complicaiton 6 th Month 7 th Month 8 th Month 9 th Month Mode of delivery Spantanous
_ 110/70 _ _ 120/70 _ _ 110/70 NIL _ 110/70 _ YES
_ 100/60 _ _ 110/80 _ _ 120/70 NIL _ 120/70 _ YES
_ 110/70 _ _ 110/80 _ PE 130/80 YES PE 130/90 YES YES
_ 110/80 _ _ 110/70 _ _ 110/70 NIL _ 110/70 _ YES
_ 110/70 _ _ 120/80 _ _ 110/70 NIL _ 130/90 NIL YES
_ 110/80 _ _ 120/80 _ _ 110/70 NIL _ 110/70 _ YES
_ 110/70 _ _ 110/70 _ _ 120/80 NIL _ 120/80 _ YES
PE 120/80 _ PE 120/80 _ PE 110/70 NIL PE 130/90 NIL YES
_ 110/80 _ _ 110/70 _ _ 110/70 NIL _ 110/70 _ YES
_ 120/80 _ _ 120/80 _ _ 120/80 NIL _ 140/100 NIL YES YES/LATE
_ 110/80 _ _ 110/70 _ _ 120/80 NIL _ 120/70 _ YES
_ 120/80 _ _ 110/80 _ _ 110/70 NIL _ 110/70 _ YES
_ 110/70 _ _ 110/70 _ PE 110/70 NIL PE 130/90 NIL YES
110/70 120/80 PE 130/80 _ _ 150/90 NIL _ _ _ _ YES _ _ YES _ YES YES
_ 100/70 _ _ 120/70 _ _ 120/70_ _ 110/70 NIL YES
_ 100/60 _ _ 120/70 _ _ 130/80 _ PE 140/90 PLUS YES
_ 110/70 _ PT 110/70 _ PE 140/90 NIL PE 140/90 NIL YES
_ 20/60 _ _ 100/60 _ _ 120/80 _ _ 120/80 NIL YES YES
_ 110/70 _ _ 110/70 _ _ 130/80 _ _ 120/70 PLUS YES
PE 120/70 PLUS PE 120/70 _ PE 140/90 NIL PE 150/90 NIL YES YES YES YES
_ 110/70 _ _ 110/70 _ _ 120/80 _ _ 120/80 NIL YES
_ 120/70 _ _ 110/70 _ _ 130/80 _ _ 130/80 NIL YES
_ 110/70 _ _ 120/80 _ _ 110/70 _ _ 120/70 NIL YES
S. No Name
47 JHANANI
48 JEYASHREE
49 DHIVYAPRIYA
50 BABYNISHA
51 DURGALAKSHMI
52 JEMIR FATHIMA
53 BRISILA ROSELIN MARY
54 ALAGUPRIYA
55 AMBIKA
56 KAVITHA
57 GOMATHY
58 SHANTHI
59 MANGALAM
60 SHARMILA DEVI
61 MALARVIZHI
62 DURGADEVI
63 ANBUSELVI
64 KALAIARASI
65 MAGAMAYEE
66 RADHIKA
67 SULTAN NACHAIR
68 MARY JENNIFER
69 ASHA BABY
PE BP UA PE BP U/A PE BP U/A PE BP U/A SPO I El.lscs EM A D assisted PE EC Help IUGR
PRETE
RM RDS
Material Fetal complicaiton 6 th Month 7 th Month 8 th Month 9 th Month Mode of delivery Spantanous
_ 120/70 _ _ 110/70 _ PE 140/90 PLUS PE 140/90 PLUS YES
_ 110/70 _ _ 120/80 _ PE 140/80 NIL PE 140/90 NIL YES
_ 120/70 _ _ 120/70 _ PE 140/80 NIL PE 150/90 NIL YES YES YES YES
_ 110/70 _ _ 110/70 _ _ 120/80 _ _ 130/80 NIL YES
_ 120/70 _ _ 120/80 _ _ 130/80 _ _ 120/70 NIL YES YES
_ 110/70 _ _ 110/70 _ PE 140/90 PLUS PE 140/90 NIL YES
_ 120/70 _ _ 120/80 _ _ 120/80 _ _ 120/70 NIL YES
_ 110/70 _ _ 140/90 NIL PE 140/80 NIL PE 150/90 PLUS YES YES
_ 110/70 _ _ 130/90 NIL _ 130/90 NIL _ 140/100 PLUS YES
_ 120/80 _ _ 110/70 NIL _ 110/70 NIL _ 110/70 NIL YES
_ 120/80 _ _ 120/80 NIL _ 120/70 NIL _ 120/70 NIL YES
_ 120/70 _ _ 120/80 NIL _PE 110/70 NIL _ 100/60 NIL YES
_ 130/90 PLUS _ 130/90 PLUS PE 130/90 PLUS PE 140/100 PLUS YES YES YES
PE 120/80 _ _ 120/70 NIL PE 110/70 NIL PE 120/70 NIL YES YES
_ 110/70 _ _ 130/90 NIL _ 130/90 NIL PE 140/90 PLUS
_ 120/80 _ _ 120/80 NIL PE 110/70 NIL _ 110/70 NIL YES
PE 120/80 _ _ 110/70 NIL PE 110/70 NIL PE 110/70 NIL YES
_ 110/70 _ _ 140/90 NIL _ 140/90 NIL PE 140/90 NIL YES
_ 120/80 _ _ 110/70 NIL _ 110/70 NIL _ 110/70 NIL YES
_ 110/70 _ _ 120/80 NIL _ 120/70 NIL _ 110/70 NIL YES YES YES
_ 110/70 _ _ 150/90 NIL _ 150/90 PLUS PE 150/90 PLUS YES
_ 110/70 _ _ 110/70 NIL _ 110/70 NIL _ 110/70 NIL YES YES
_ 120/80 _ _ 120/80 NIL _ 120/70 NIL _ 120/80 NIL YES
S. No Name
70 PANCHAVARNAM
71 KANAGA
72 PRIYADARSHINI
73 MANGAYARKARASI
74 ANITHA
75 SUNDARI
76 NAZRIN BANU
77 MATILDA
78 AASAIVALLI
79 AFREINSITHIHA
80 AARTHI
81 VELANKANNI
82 ABIRAMI
83 KAMALA
84 BARAKATH NISHA
85 NIRMALA
86 RANJITHA
87 PUNITHAVALLI
88 THINGALAVAL
89 DHARSHINI
90 DHANYA
91 KURINJIPOO
92 TAMILARASI
PE BP UA PE BP U/A PE BP U/A PE BP U/A SPO I El.lscs EM A D assisted PE EC Help IUGR
PRETE
RM RDS
Material Fetal complicaiton 6 th Month 7 th Month 8 th Month 9 th Month Mode of delivery Spantanous
_ 120/80 _ _ 140/90 NIL PE 140/90 NIL PE 150/90 NIL YES 
_ 110/70 _ _ 140/90 NIL PE 140/90 NIL PE 110/70 NIL YES 
_ 110/70 _ _ 150/90 NIL PE 140/80 NIL PE 150/80 PLUS YES YES
_ 120/70 _ _ 130/70 NIL _ 120/70 _ _ 120/70 _ YES
_ 130/70 _ _ 120/70 NIL PE 130/90 NIL PE 130/90 NIL YES MILD IUGR
_ 120/70 _ _ 120/90 NIL _ 130/80 _ _ 130/70 _ YES
_ 120/70 _ _ 100/60 NIL PE 130/90 NIL PE 140/90 PLUS YES
_ 130/70 _ _ 110/70 NIL _ 120/80 _ _ 120/70 _ YES
_ 120/70 _ _ 100/60 NIL _ 130/80 NIL PE 130/90 NIL YES YES
_ 120/80 _ _ 110/70 NIL _ 120/70 _ _ 130/70 _ YES
_ 110/70 _ _ 120/70 NIL PE 140/80 NIL PE 140/90 NIL YES MILD IUGR
_ 110/70 _ _ 110/70 NIL _ 120/80 _ _ 120/70 NIL YES
_ 110/70 _ _ 120/80 NIL _ 120/80 _ PE 130/90 NIL YES YES
_ 110/70 _ _ 120/80 NIL _ 110/70 _ _ 110/70 _ YES
_ 110/70 _ _ 120/80 NIL _ 110/70 _ _ 110/70 _ YES
_ 110/70 _ _ 120/80 NIL _ 120/80 _ PE 130/90 NIL YES YES
_ 110/70 _ _ 110/70 NIL _ 120/80 _ PE 110/70 NIL YES
_ 110/70 _ _ 110/70 NIL _ 120/80 _ _ 120/70 NIL YES YES
_ 120/70 _ _ 120/70 NIL _ 110/80 _ _ 120/80 NIL YES
_ 120/70 _ _ 110/70 NIL _ 110/70 _ _ 110/70 NIL
_ 110/60 _ _ 120/70 NIL _ 120/80 _ _ 120/70 NIL
_ 100/60 _ _ 120/70 NIL _ 120/80 _ PE 130/90 NIL YES YES YES
_ 110/70 _ _ 120/70 NIL _ 110/70 _ _ 110/70 NIL YES YES
S. No Name
93 RADHIKA
94 MUTHULAKSHMI
95 MAHALAKSHMI
96 RAJINISHREE
97 JASMNE PRABHA
98 ACQUINES RANI
99 ILAKKIYA
100 RAMYA
PE BP UA PE BP U/A PE BP U/A PE BP U/A SPO I El.lscs EM A D assisted PE EC Help IUGR
PRETE
RM RDS
Material Fetal complicaiton 6 th Month 7 th Month 8 th Month 9 th Month Mode of delivery Spantanous
_ 120/80 _ _ 110/80 NIL _ 120/80 _ _ 120/80 NIL YES
_ 110/70 _ _ 120/80 NIL _ 110/70 _ _ 120/80 NIL YES
_ 120/80 _ _ 110/70 NIL _ 120/80 _ _ 110/80 NIL YES
_ 110/70 _ PE 110/70 NIL PE 120/80 _ PE 130/90 NIL YES YES YES
_ 120/80 _ _ 110/70 NIL _ 110/80 _ _ 120/70 NIL YES
_ 110/70 _ _ 120/70 NIL _ 120/70 _ PE 130/90 NIL YES YES
_ 120/80 _ _ 110/80 NIL _ 120/80 _ _ 120/80 NIL YES
_ 110/70 _ _ 120/80 NIL _ 120/80 _ _ 120/80 NIL YES
